var title_f34_38_35424="Photomicrograph of urine sediment with a red cell cast";
var content_f34_38_35424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with a red cell cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing free red cells and a red cell cast that is tightly packed with red cells. It is more common for red cell casts to have fewer red cells trapped within a hyaline or granular cast. Red cell casts are virtually diagnostic of glomerulonephritis or vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35424=[""].join("\n");
var outline_f34_38_35424=null;
var title_f34_38_35425="CF atelectasis2";
var content_f34_38_35425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right sided atelectasis in a newborn with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow up radiographs one day later. The condition has progressed to complete right-sided atelectasis, with mediastinal shift toward the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan D Finder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35425=[""].join("\n");
var outline_f34_38_35425=null;
var title_f34_38_35426="Tuberculoid leprosy";
var content_f34_38_35426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculoid leprosy (TT/PB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 290px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEiAasDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC5438Uw6HY3WozlGaIFYY8/ff2wPUj/PT57gubnWLx9T1WTzZ5CcBnwEGcgAZ4UZ4HFHiDW5vE+um5fP2OE7IYxnkZ+9g9zVuAKkWNybFdNvIRmXvz6dK48bXfwI9jLcIopVZGrbQBSULsVU54BU4x6555A/yRWnaHcvyjj+714BrNtlDGNQFVDkgEkbvbHQ8df699a2kaKdi4DZ+7kDp27fh+FeFJ66nuQV7XL8CfM2wfd5XnhjWvb7ZIj8wzgg7j/nisBVP2lZRLKMx7Sm75fXdjpn39614nG3bEmUOMsRzjnpV0n2NrO1i5ayK+I3KAZwcCrUrKCskeWIfDDIHTr/n/ACc50WJgUjG8DsMZIOcGrabY4VVdwPXO7r/nFaplJLoakJzJls7QQAQckfhVqFyGaMht3c1QBR3d0PQj8OPpV6MpIAw3bmPJAxz0oF6ltHBjHCBlAKgnr9RUsagyIig5bpk8H3/+tVZ0OF3gr0wM9M1K0hMpVTg4JDY5pk+hKpEQ+bBkzk4GMelTDL5EhAJPGc8/59Kq277wwfcr56juMA06VmJ29Mjg9v8A9dDYJallXWOFlC8A4wWzmnNIjrwDuXnjj8MVTkj81v3ZwBwQW7d6WJmEoKjavTP+e9IaSZe3FhEEUbwSfTI/pTw8iPuyNoIyMjn/ABFVGPkMcsd2QBnjFLPcjYgyNw7r0/D0pBbsW4YcOXOCAuTvPH1xThEj5kj28gYBOP0qlDcYVlByCee4/GpjKu1QsQ3gbgW+lAWZaECLE23jAyDmjYHQMcjp8vX/AD2qtGWkQK2T2PbaOasW64wBjB5KimiW7DrMPnCcBuCTxjjpVuC1aQqGw4UkDnqPWlt4l+WQAB+uCODzWruSIR7BwQc8Z6VSiZTqWehTeERIu6NkPbnj25qZIyYiNuSR36//AFqtOxSMEhWB+UDof89KikjMuNyhcEkEdzVuJjz3GbHMQXuBgEdOlEURUFXXax4JP86tQJ5QBPbtnPXrTpCrqAoHH+evejlJ9o72IUtkQq4bceo9acudrfICOnTqPWgAtNmQEoB91SPwpHLSSHP/AHz6j/CqsF2yxEwVS2Dg9cnp/nNTNIhVBjA6E1Xi+ePYclRk8t+lTrEdjHDcevTFUZvzHicRZCEKD3/nzSYMiqrsRnr/AJ/Go5eMHByxICdc+5qWNAirxuPQKW7DGTRuLToJK53GNOV7jHSkmXbC/lEKyjKng5NMRkIkSTcxBxgdz9fSlYqJGVNrgjBLdBRuPYh81wMSks5X5QDjk98dqsx/6nZJgxtkbcgk+tZd06I0hTLyEbW3/dA9RUttO0dmjw7jnhc8e2RQn3LlC60LUrHlACAvrjI/Gk8w7yJIyOPvAZB44600zMqs828tj5QvU+uajDb4Q5RivQhT/n/IpkpDgwdtoxg4zxxjtUDRtvJymB0A6mgEJ8rq2A2OvpTi5W4XKkGUcc42+35Cp3KV0Uiqxt5I2gYPOMHOfrVeRVEjfIpLfLuzz19qluYy8u91GM4wOcVVebJZUzwcKq+pqGjdFSaQxsW6qTjoahd/lwo2d92eBVqVmkyGXbgd+/4VUuImfgZ7dD92pZsmupSYMybGORknHX/Paqqur71X+BgCOOv1+lSOT5RXBLnAweM/5xTJkwnyBsOD1PUgdcflU2tuaFSYAxTggqDlQQPw49+RWTehI4gpYM7Nx2INa0qsqJuJyQOD0yDzWZeQlGD7QScYwDxUvQuLM+5jG5DlSGG7bnPvXPzBfNkCMsYbGBgcf54710BgklnZX+7/AHRgAHjI/Ss7VCkEm8KAXbHpjnFY1EwMWSMsHBK5/hBJA7cf5/OqsxPmNtQkflVyViWGMEDh+cfgPWqAdUG3eXx0Yk8/59KyimZtPocnpsccNoFIIYjoVzkZ6jnn+Lj/ACNC0VpIz5nzjy8kKSNoHf09RgetU43SIHad7uOCcYBznp/j+VWrOQDeVIDDDbiowDzz6816lS7uzlpx5VaJt2WFSThy6sQWHI5POPTkZ79ua04RFFNtDAjIPy9+v/16x7EKsWFXKgFizYGcE89ye30wK1U2i4dgVbAAYqPbI/nXnz3ZtHqXyoaTIzyD1HygVYty3mRKik7RkZB9/wDD2qvaTjyz5pAA545I47++akLZbYiY29unH/1+KEax7GhCHkYL95uu4dD/APXrQLFVhVcEKANwznPfisxJHUAghvlwPcen+RWjaOrR5KgAjgCtVqV5llpi8PygiUEsSQQDgH1+tacMw8oEnP4Z5GP8/jWXGqwMy8fNg5z0xU0U+AdydOc//W/pV3Fa6NHzSy75juPXjt7UyWXuMbsY6ZIqO3cvFyu0nBUH86kjVY8kg7mGemfz/Sh6haxPBKrxiMA7iMDA4zUjAujI7EY4AIPNMYRKVKMFyvUjkU1JWRykbANg4bPt0FAkPUtv/dtgr37D8as+XEqqWJLsPvHmq9qY/IDtlgnUj1q0HWdS0Y+6eh7dqOoO9yF97MSzdOlSBFLjzEzEO+Of89P0qSYBoVXazMOM44BpIpfnEZABBxknNAXJFjiZXJJw3bHU+oq3DGfOUMFHoOlRmNcnYowo4z2PrVmTcEVSquDzjPYj1pmTb2HOoabEhUjGGYd6ltIycnkDHUjj6cVTtY3UrHuPltng8lf8R/n6a0JLIqggKOigYPvTSIndaFgJKkKbUUse54xzQV+cEAooHLDgH6f409jui2lipBxt6ZpJEVQdxLZ454xVIyTLUMamNcKGzjA61JDlnI2gMBu+lZdrK/2wLhsY/wAmtKSVTnccIv3iO5//AFVa7mUk72JX2yMdpIbGOnGfyqFEj+0hSSr5HXGPw71XhvS6nC4YHOG/hHbPpVGa/ge7WOFS0u75mP8AnpTuVGnK9jYdi022EA57Hp/nrURuYYzgtvdf4lydo6VkX8jnyvLkJRmOADgt7njp9Krz6ikDi3jVTsG0AHl2z1PtSbsXGldHRxyxSwKWIGHwTjODWgtxmM+W4bjAGMg/4muQspm8olvMkRmxgDBc+w9BWi94sV1HbQbPMYjJHOyqi9DOdLWyNclZPM3qxZeB8pAX2qBLg5dSo3gnj+lKsnljEQZgDgP1BOOx79afcBDAfLyoIBUdT35pPuQtNBsDNGjK4XI9F6t6VALT7QrSTuyqpwPf6Vp20LOirjBHGMdD60/yNoZItyopG7d/FT5Re1s9Nzn2RTMoz8mchcckVbEUr5fPAbIQAjj0q5dL5e2VI1LrwD7+vFVUuJmIVtm/Jznp+NJpLQ053JXQLteYmRhk8bOvPtSyEJITJMI2XkKRxSQjZflN2JM/M46fhVl4d44wVBOQeaFqKTszMuJLhfJZlj2KuPlUKCPX3pFkdV37jtx36irbKqurNuMZOMdCCaguAggzGyruBwQckD/P9aHdFRkn0KUYRCwdgHwQ3se1U3AmCqjEJu6dCT/T/wCvU4AWGWWQ7SvfAO7A6VC8e6bcqAOe3TB9MVPkbrQJFCwt5rbAxxyScj61XuUKfKgIGM47nipruFXUBsb+uQenuPyxVb7QpjYTkFhwc8E96TGvIw4XkZwSU8tlDK6nOef5f40243mZV5KnHA6A/wA6szqWmVQuw5ztPFKQkSNlfnPHHrj1/Gpsb8xjOLjzJGnP7sMAmOw5Bz/hUDyMzgMTtI4B7/54/L6VcvY5M7gNoUg4xyRUHlnJkJOMnKtxk9/wqbF3TMlFffL5jkDnGTwef/1VRuo/MDhnyScjB/qfxrWkdm3ZA3bsZ/vVSACruIXdjlSO+elRypqzBMxZYnZZGkUOOVC/p+NZ/wBlkPIBPuCef1rYuATNI2Qyg/KF9OD+FU3GHYKqnnrt71zTTRDfY83Rw0YBLEcEY9P8/wCeauxwlATtRhIQFLHkEAHA9ufpWenA4Ht9Kv2yxvMqnIXkHauSePqa9epoYQ01ZrWkDqq+aQM5IRjtz0H49u/Oa3LcqFG7aVwQAMgE9vpXPJMUkR44S8h4zk54J5H14GPbpzWtanZuTOduAS5wc4yTn6Y/X2rzaqe5qk2alvt+VnTGV2+p9s/5xV23RSWOXJbI78+3tVK3kQSRg7VOT+fUdfarzyLk/KF5KnHcZPp7YqIu2tikTW8attZHO5c5C8jkflV0ZMaxuu0LyzE9+f8A69UbYsg6E9ie5I//AF1oBmI5+cZ4b0/z/n32g3bYrrcsQYZgWHAB4xj86sW6bTlo02tyVJxziq6Ow2+WAdwweAcj1rStRGArMvOB97BwTWiY2x4CyQ4J2v0ALfl/n3qywYIy8BlA7ciqrHcG+XJHOV7+1TNl13ADcT8wPcY//VS2EwRlBAcnztpHX1p8SbGClQA3Q9xSKQR5jjnsM8inQbnYZGQp44yT6GgCd4swgbsMM4XoPr7fSnW6lUkwQuDzjrTGuFDSGPHPbb+dWIgFXEgBzgfd6cc0E7IYkDtjcfkYjk4GalgibexT1wDxx70jMZQVU4CnPX/61SwMeGJJGcFTx/LigTvY0Qg8rAVMqAFOB+uOtSRLiJtxGTxx1qJ0aePYBjOQxHBFTQ2ro8eWLMRyG56etUrmOhLbYAJYEp67qsqdsisuMADpxj/OKh+6N5Iy3UAZ6U97lXyvyqMfNxj/ACKaIkrsmEiyttwpcHJI71YI8pMMwxtAA6/lWarxwtvOEQ8lvT2xUc19HJukLM0a8DBwc9uaaYcjexcu2FuC4Xgd/fvUKXSyo4MbyLjoF6e9VLa5lu1dNn7tRk57D09zWoERZSlujLgY3A5yccg8U1rqhtcuj3KVwBDEXVHBYABDkk9OWqtb2v2yRgY9jbsDB6j/AD3NbsdpIwZWzI5xuPXHtTTbMrsI2KIg/eHbxzTs7kqpZabmbHbQmQyXLSjZwJDydvYAZ/Wo5LMLcLJvUXD/ACqoOWUdsmryW7XkmfmSENy38uf6U/7E73JKgxnO5WPLE/zpWK57PcS4gmtkFlC6PcAhmZDnHsPerWn6fDDblZFQzMcO24/IMdfer0NsUlAjSOWc5XdtwFHr15/GpI4I/Ob7xj5IPTdzWiXVnI6t1ZMS1CAKkajy0GA3Td6nHarUEayqxABccAAZAqSCOOVACNm0YAHYVKqpFGEj+XPB296tI5pTCCNQcKvJPJPrTvKREKn52xjHSpN4BJJOBzn1prSbWBWPcoPrTM7tme6MEZWGWx19fYVXiheSYo0HlnHA9f8AIq7PJtlY7OQvBJpMt5YkP8XXHUCpauzdSdtCutmkPmMqLkD+vb6mmSbihGFUtgANxj8KlbcuFRsHPJHpTZI1IjdgN4Oec8c0W7FJtvUz5FMaKsiuxJwxx/Om3dkPs/yxjYeMDjitV9vG7GM85796q6kZXgxBHw3UgdqVi41G2rGIkZMhj42j5gB1NQ7ZIy7M24l/vdM8nGKvyW8wRjGH5OAw6n8O1UjKEYmWM4HzY3bu2ePfOOazOtNvYq3Mf71mC5GOWPr3/TFVXtv3SkHaTyO5rQbMqhlBCsB8vXn3/DFQTPC6ncOCxXIbnP8AhSepakzPkt3ZDsxuBBBz+mP89qryQSDBz94/MOmCKvDhDiMkZ/iPSowzM8YlOWII+bjFTYtSMuaMhhkbBjkDnP4dvWqdzbh8qjc46D6/WtJ3MjOXBAPHP6VUmSMBtnRcfdPJNSaLQyUt1JZt4GCclhyP88/pWJqJWASSSTNwck7un4ZxiuhZI7eI4GNxzlj1NYclumDuUyOclvbsM/Xiokm1Y0XUzZUBhDFiQpBIIyPoTmqU6XAmcLtxnuprViBkiIAULjG08AdP8c1Dc2qmdijEKecVjKLeqItY8pRm2BQWJHTnoP8AP9a1LGQ7CrJIRydyADJOOM4/SqaYkGI1dmbAHz/d/wA5I/Gp7XYpZDIGUY4YA5Oe35np6/jXo1NUc0EaFsY7j91ICEVT04xgYzj16n/JrTtTiPALliNwLdM59B0+nTvWZZMgl/fKNjZTLnpjpkZOOv61pW88ZDKoaQ8Z5wPmPHb0P6VxVfI2u9lsasY2t33Z68dPpn6VoW+CC/ULgZAxurHhyztCRhlxg5PXA5J79P5VpWpZBHyV2kH5u/8An/OaygrMdy2BtkBzlsYA6YPWrdvKxUEDB9jgE/z9KrCYvEoA5frg42nHr6VNZ7tzt/B6NnKnpWy30LWxqWxKKMHG9eOnNXI2MMpdi23nPp71lIcIdwG5jnAPHt3q5FuZmIbDdcE5q0DJcFpSByGPpz/nirCOy3BdBknjHYcVSKKqjg7SwyQ2QTVgNhsKrJnGcg/j+HWhIbZZQkSM0u3Odzd+vSnh2k5jHI69B+FRi3kkkZkjZ4zyc1PBsaNiF2nO088HmgV0WFHAAwHI5z0+lPlYZUOnscdah3nYu0YZew/nUtu7yMHLbvYd8UyfMmRPMlTytoyce1XUtwQcgjBx0z19Kr2sgba6ja/uD1z/APWrUhm2naSOxOe/HvQkZyb6BaBo3BIxz2qeSVkYZOAADjFUrm6jhgDO52k5ABxioFlZ1DMGAJBUKPvf/WxVbCUL6lie5bJCowQnnB6L/nNRu5leJokAUHJLHk4P61OLdVkIZdzAA/eDDP1/wqxGkKzAMDjA3f0FHqHMlsjNmSQgsi5RjleemDycVPEucbFUyOMBem33NbsaCRQVVSOi44qs8MYGeW5weO9OxCrX0ZXtRHAiE72RscHBIPcj/GtSAqy4jB2qRyO+f8nmq8dpI7q0qHYD0B69eorTjt+VAAyeDg5FNK5hUmh0RELlQSuRzxkfgKPKZlfaGVTy2SOe4qbgnbtGANuTz/KrSqPKyV2qOAV4zx61e5zuVmUgxe1WBcpFuJLDksantoj5YCsxd+FweT+P50qQRkBpWJAGccYq1CFQ4QDeRnk571SRMp2VkQNAY0Kj7ucnscU5FUsF5LHk44wB71IgOfnI65qfarAEjrxn/GmkZc9tyv5YX5iDjOck9qmjZY8HrnPBpwG7cuF9zUDJjKxjJwOnGTT2F8WjJQwMqlTjHYih0VsEyEgnIAFQKMAh0Bfpt7CpVlYnB4JPJpBbsNVNpIx8oHB71Xk6jO75umP5VZllHmYKsCe/Ayaikl2kBRgk8njj8aGVG/UiulXcMkqR0FLJzGu7j0z3571NEU3Mzt8uMCkuAJXGMdB3/WmO+qKcsaqQ7lSvYkng0xZg6sxTczfKMnp+FMeItIowxZT8u1uO/NSSgiNckYHY8Z96k17FaQne24kKDkDPGKybuINcvIShV8nAHPHp+tbvkxMqq7Od3JJzWVdxLCrPB8+OQW5I96mSNqUuxlmOYYiwMcsSTwoA/wDrUkwAEYjVtjEucHvUwk8xkjVQ0rZJL8ZJGM/pRIdyRRrhei/j9e/SpaOm9tzNliA3LuLDODio3m5OAO/OP8+9W5F2SMVTcAv5nuT7VUkjnkD7AAdnG7gc1DNFZlNwzE8KxY8ADB/P/PSqsikMqonTIJ9PfP41YWCWKNPMKl1GG68frUczxIxYlgSucZ5NSaJmXdwCZWDht45AYjjoPp0zxWXfxxhd7EEZwwAyCfcVr3TcMFBJHXaT+f8AKshreQ7BFGjjIxu6f560rmi1RQlK26LvfGW7ZwMd/bvTI5lCD5ScjOcA5zWhOodiJwrHJDbew9qqlIgSEVwoJAABrNqwn5nkoQocllUEfeXGT6nr7mpBK5Z0YfM553H6nPr7/gOtJL5brH8uQR0U475547f171JEpiJZcFFGQy5HPY/z+ldjempxweg+3klZ1dpQATtLEE7R7+o/MdavomLeQ26rIoABLLncMk8e446+vfvQdY5lTZwu4gHo2D0z3Pf/ADxU0duoDSOyLGe+NuRjsM9fzxWU0n5GqaZ0FuuJIpfuMF7sRnp9een+RV2Bi6jad7b87933sjr9Ky7KYqhSYMwEeFBOB14II49vw/KdGlVY9uN+3DAjA9uR9McCuJ3TLubUDhZN2CRnJzxt49vzq4jBWHmPksuSo/kDnpWXakGV2MakE4yRgHv/AFxV4sQo55I9QAfr+daRkjTcsxujElmCgkY4z/nvVqM4AcfdJ/P2qhbjcFEpzgbeDjkcf4VZidpwUjdSinBXd93n9a1XmBdikYIykBi3zDjBUDpVq0ASQiU7mOCT6f54qKObMLvuJcAbeBz+NLGWEjs/8IznHt0FO2ormpG74aRRtjXIOeRUKOrbTg7m4PT9T+dRB1aDYc5PPsB71FbylTuG3HI9ccUCSNVFC7gCdpPzD/PSp1fdgcfWqJUlwEyCRkA4xWhZHOCwZiST7GmS+5ctoAI97sVAJA5/CmTzEzIsQO1eN/0pTMEO0nDH7xIx7dKbGRIW8klMnJP0pgk92TW9klxI298hCQQQT+VaK2e5jkkzDrngfhUsaoyq4IV2PYYHvgAVoiNWG9So7H1NOxhOqyvaweX0wR6GniGQE+Yods4z0xmtCCPCsCx49sUw5Z1VT8oxgkH8qqxzuo22JEgESxnII+7j0/PipvKBTdu2KB1HFAZo2yy5PqOgpFUSg7gDt6Y4p2RF76irwxB+5t4Oec+mKnGHjBAfacYyaZEAIySFwvrU0MgdGIUhuckDmqRm2IC6Rls4zxjr+VSJNnYSOAeAaZbhskODs/zxRLCA+5Rg9WyMD6YpXe6Fo9GTAKSTjAc9CKYZhuUguPT3qcbXKhX3MvUCmMSVCtksCcHt7VVrELXcuRsu4lQMnjp0pszIMAuSSSOuPzqpGXV2+ZdmOmOQKmZiQGQdeT6/lTuRy2ZL8m7cSWDc8c4/zmm25VpNyH5AOaQswBII8zB4PIz2+tMJw21B8x7Ac0xWuSlwSQCSOv8A+ulHzBRtIOP60yHcz5K5O4gE9BirSMNuEXd39+lMTdtiCVU8wED5hyMUydIhywJYjp6VNIWYZAXdjkmq67hIAY+v0OaBxv1FaFFVgwGwjGKbMo8tucEAYqXaHjY57cjPQ0x9y9Og4HNA09StMc7fLB45+bgGngbocyYz1GcGnttj4b7xzj/69NMYJwQWYjnvx/KkXcjlPmRneSvOMgct6fSsu68uNG3jAPILdOtXZxOVwF/dg9OhI5496qStEwEd0Mkc8DgHsP61L1NqasYcdzEZHk2EKgIXHXmhmQbPlUu2SAevv+pq3d+VbQTGBFdyPlPQc8HA9etZ1xcSKXUKBJu9Mkc9B+FZvQ7V7+xBdh4VMzLh2GCAOv8AhQhaSNC52lj61bCtcRLk7SvPJ6VH9mkCgl8BecggH6fTA/WpZV9DOuoxGWcswGeQevFVZW+b5IxnGcDA69a0rnEamYhjKTx3wc4/wrPm+dHZMbvQDqahmsWUYw/8UYHcH8qpu6K7oNqyMowMdBx3rXKSSeUGUnnrjjj9aybmALu2nktjGM/j+XNDNFroZjIyxYx8oBGSP0qoQVwC2SB1ArVKK7Mrb8DOBnHv/n61TljTzGxGDz6Umim11PHpENvdNb3ERBXIYMo4IzgnJ44xVmNxhlfDuR95VAUZOM+35df09P8Aix4JeWZ9Y0uJd2MyKByPevKrVn8yRHRVZgFyy4I68cdMjOfpXZiKLpvU8LCV41YcyepJdFPKCldpjIyQADnngDP1PHH9VAjnKxzKWH3iUyxUjg556k/n+OadcRKGz8qyDB2uByO/Xrj8f0pgEariANuBJY7DgnGMD8yOlc6emh3xmraF9SzAS7V8nKgjIJ2KvOfXp7n+ug0u18y7Q4H3hnJx1GM9ORWNbSsyJHKduAAHUYyCOOOOOPx96tb4HZ+jL0QH72eD6+uOPQE1hOGuptFvS5uW9yvlh2UY6AEevv8A1q3Cx3jKncxwMnPH+NY9nL8w3rsc4Vl64+npx+XHWtGNo8uqHB5CkZwO3Pfrmslpv0LvbQuwO7oo4xnBJP1/z+VX4TCEfPCngfLn/PT9azbWSPcgRckDAX1/EVpQIFIKlSB2B6H3/I1rBPqVctwgSBXChSuduV5H0565qRZtt05mUg4+8e/b/Cq8co2l3GWJ+VcDpmjfG8gZWYN1b5citRX6lu4mjlZUOQcckinWpEZLP94dTxwaptPFsjJGCDy4Hbr0q5D+8YttIyOD6e+PyFFrjUraGrJIz23+jqC+zjOAufc1fsJma23sFQldzLnvWfuC2g3BvUDj6/1NI1yYVBwSV5wMU76gopolmupZNigNtU8DGcf5zWpp7SiSCSQlzhVHHoMD9KzLXY0mXCmTucYz/nmukhRXhiFuNrEY9vwprUmpJJWZqW0RKpnoTk49cetXI49hDbs4PI681VtJMYEmCoXsuMVbUkhigBYKO/erRwSvclWRd5UYBxn0/H9aehIGB949e/FVimMFyM5yTipYZ0L7Dnjv/hQQ1bVDsFmIyQCO1SSgqSoxjPX1FIoMY3HHJ4PoOnNPkBCDgFiM9aCXoRI7KSGwMc+v51LuDFeQAO+ev0qDc28fKcHvVmBcbe/WhMT7ioG81WUg4wBnrVlnZwNvtxiojuD+hHPFPjZ2k4I259Ouaa7Gb7iAlBvILH09Kn3bIztC8gkf14o2CNTgYyTkKOaRU8z5WB8sjPpinsTfqxIYWw3mFweg46mpAjFdpKqQPlP4imnYrgDcn93vVkc57k8en+TVKxMmyEsFlUZB4wT1pyhOSOGA9cn60jAZYHDDI2k0pwgXCHJHGeKBbkmcOoXBBOOnI4qaON8swb6A1W+Z8clGY5BHNWEZgqjOQAQc96aZErkUhmOCCvvkZxQrggHqR0zipMBhkjoDkH0pPKB+YDA9e1MLoj8rbvJY/N6DFRCE5yvTHcfpVvyy5OxTgnBP61GwAkI3ZI4GB3p2GpELSRPMoTBYZJyR8v4VCsUizMxI2DpjuOKnuFUoxAAfpjFV5ZXIiiTPOM/SkWr20HzlljJTaW28DOBz0qk0W6JSw5b5jz0NSOTHgRszdyG74qOV2iQyOpJxhl64z6VLNIqyMS5DHIeMcvgAZ7f596iRBM7NJt3Mdo47VsmaNo+VKyEcgdPqax7l/LuMKPmVtvH6Cs5Kx2wk5LYbNCWc+Xk8hjntTCxDbgWZ+h4yP/1VdWBvmk3EiQjI/nmqske+IM5A74696T0GpX0KVwP3JdmX3OODn0+lZybJJiIwwGQPlAHPrV2+Ep8tk5R+oJ7ep/z2qDYXDLkR7Tz9M1nY3i9Ct5jIuGZcqOGJ4AA//XWPNG5mZidpPAGe3P8AStaRfMi2hNq5ywPtVO6Q/M67cNwSxztGfbvSNUZRjLA7iBkFRjgDjr61myTFXICkCtSSNYlEa7RkEHHX3P6VRaNixYIMN8w/Hmkyj1dzBd2zJKqujDaVxkEV4V8TvBc2hsbvTkaWxZi3lkBghOf8a9ktZEDgq2HP+P8A9f8AWtRYorqAxToGRlAIwD3r6OtRVWNmfA4eu6EuZHyCjiQhXMS7AVy4JPA6jv36VNCT++chTHnfuPUdevOc/wCPWvRviZ8M5tMll1DTGDWRbcy5wYwc5PTkZ9K8pFx8jqMjcwJAPBA/H/Oa8mpRlF2Z9RhsRGtG8S6Q88m2KLoASFHUf56fX8KVHcuwTD4YkORw2ASTmopboFGjRgVweex9PlJwPyq1CqSW4dpGdf4QfvnBGRweM++axei1OuE9DQWaU7ZthALhQvUtn19B249K0FmjDMibCcKWAOMDsB/nvWbHIYppJDL975cMrHHAAHpnOfy7dpkkgYx8B2AyQACQOc8f56eprkkioy01Oht5AoJwQTgrn16fzqxHLtKbsjo2T39/1rBinIt2MZwXB2licH0PtVgXQLGP5iUwGGM5yOOR9KFoU522NgTLIr72wwIwN3HHXmoVmyzsSCR1HUEd/wCVUo7kFyPuCQjC7sdupHTNMExdmbhWfG3HIABwf51V7sOe5rLJyhGcd8duc5A/z/StexcqrFpM85BJ6+1Ytjufa+7Kg4Gehyf6nPat62iWK2gkkXMbEheeRt74/H2q4JlJ3NcL5rLnkYA7VC8SI5Cvvds5G77o45Hb/wDVVUaikXCEOXBGB1xVcgz8EqV+8ADyfT8Kp2NI3Oj0mLeehKjuerZ710UDIibuFaPjGevH/wCuuZ0kNGRu+YDDZJyf89K6GwhR1RpOQH3AHPK9xQmZVPM17aPA3v8AdfkDbgVdGAoJJBHoP8/WolmzKdimNBuGF5x9KWBw8gAYAqCTg/zq/I4nd6sUk7yrHrjP1qS2VTgvUhyyKHUYDfd6il83MgQZDDr3PvRYlsmyQi/vBtzTpAN+AAU9jUMZBYkM+c9fSnTAFgVYkY5PTFMixFK5AOFzjnGKtQuhG7YQOuTVYsFyoJOeee1Pt5EZV27i390Cl1CSuiwMM2c4U9zTgdhYAljnj1P0oEu1cIQcdhQqb03NnOPw71RBYQNIPm+XPpU1upRNvIHAz1zUdujpt79alckN8+dpByRVIxfYjuExK2FZucnFSKdpyc88jjJqeLMkbn5eDUMqOGG3qAQAPSnYnm6ETsd4VhlT3x/n2pTE/DM2F6jP9acrEOvOT0Iq0kayHJb5x0z9KSVxuXKMhiJHX5l79v8APWpUCk5c4INP2lR97knjA/M0xQQAJFOCARz+vSr2Mr3HqFDMw6kY5xj/AD/hTAoHKyFm6Y9fpS7TvG7A2j7xqKZwycfNjPToadxpXHrgtlWwp6jdxUciL1UEN1Jyev0pY3AkK45xwT/h+VNnSTIORzxz3pFLRlSXdnbISFznP4VFECFZjgAZGcdqkfhsBvmAODjjNMiib5eST/dFSb9B6pHLHwmFHLcVTuTO02wLlT/ERnjj86vSs8ShT14ICjAH1rPuW8+3YPI8QP8AEpwQf19P50MIX3KLxLCzPJK6uRzgdahaPP7xI1AxkBsEk+uT9c1NqFuZGj3NtVQDnng+tVraZY5MA5RVz8w5x9O3es2dkdY3JlVTb7kIwMjOeOvUHPfNZtyZZwH2iMD7uPT/ADk1elkRlTyn2uegHT6/pUE8DsqxoWADAOw64+lKQ4aO7M2RcAnLPkY2dvbHpVWQM2/kj5uVzjP1rUulCFtzhWzjaOff+grIkic37EAeWD94jHfioZ0QaI7iVASgUkgfMQM/iapO3zuo3bTzljwCavXu3KDBLj5Qq8A/X8qrO6+XtjZd4x0H5jmpNUYeoHMmwS4zjJzn3yPSotqDgkHHGalnVpbppQUUsegHAA96hlwr4IUnAzj1xzSehe6Oxs/kAIIH8jWzZyhF2jaPYV5RD8R9HQc3cAyO0q1qaX8R9GkLIbqNiORiRT/WvqHJH597OXY9KuJEljKPhkPy4I4rzLx58LbbU2a50hFtrojlc4U9hxjFW5PiLoscqhrlOO5YDrz6/jVfXfi9o9naHyHEkgB+RWBOfTFZz5ZqzNaXtabTjoeIa1oGqaBcMup2jxYb72MpnNUYZR5oYsqgNxnOAPX1x/nmut8SfFYatbPbtY+bE/USHGPoa87l1MPO7rCEQnIUHoK4p0L7HtUcwja1XR+R0sdwXnQFiR8pHIxnoM+nX8PerL3CzwuYmxIBggHoPw9sfp161zdtcrIpAc8jkZqfz2BG0gY4GP51ySoanpRqqSUonQwXCnaJ5VWND/qyBxwfbpz7/wBacbxBtG+KUoMgvnP+fr9eKwDdM2dxGcYDAAfhx7UiXZR4yAMocjj8s9v071H1fW5XMkdTHeYd5BtUDK7QuSOewH6k9z26U+KUy7gi+WHAz8uD+GD68/j61zEGoSRHDPxhuozjI5IFa9vdvPOAVIRdoKqpGV28Dj6n8+hrKVHl1IbS2OysXG1ehTABdgQSenH/ANb6VdF4ftQRHVN4wWI4GPU9gfQc8fWqGng+UI1fBjAwhAJA/wD1ZqxbMRLuZSuOpIOB7jB9v/1UnodFJ6FmGGWSZUJAYn5R3/z9MV1VhZH7OdxRPkJ2sTnr/niqVkisymPIfZ1Axj8PSuht4neffOSzM2cdT+XpTSsauXUmsoo2dXRWi5yGUk4b8PrWzZFogcls7snJH1zz/WqscYQjuu7gHvwauMv3UK4Tqw707GEpc25owy72/eY3LxwOvfiph8oYxkIT6fnVO0I3GUcsOCDVuGTfHjf0/hP86Ec8tHoNLsUBZmLZ606P5G5zzgfKMfpSswVOVyzHOcYqRYyig5AyOpPPegV0O3RpGH/iPIJHP6VKSCoD4O49sHj8aqTQ5Awu0Dvj1phZoztBzGeu3uad7C5b7FxAvyAnj1I/nSxrhnIJyc4oVSUP7zcQPSnQKsR5DYbkgHrQTsWYCCxHy7scnuasKoG4rk5AGDziqo2Fyqndgf5JqeMeW3TPTvjJqkYy3JkQAksx9SeuParcTK7BTwfbvVeJlblgcjt2FSljnYFGOvAq07GL1LMgK42AAk9D6VXmHl4DPjPccmmI8ilg33OoOOv09aZJukcgjOeDRcUY23HRxnDENk9ie3sf/rVPIDgtGQAOnFLb/LtAA4zz6U1m+UZJTvuK8fjTsrC3YI2VLryfRv1p/m7kRxk8469KRjhcvjI9D70wFmcKmOCDnsKAtfUWVmMgPBJ7A9cinoVA+b73QinhVQAPjJBPPTNLIw27l+93UciqasTfoQOBG53ABm44qORXbkHoOvNTymPaAR8x6H9KilAUghd+3OSelFi4sr+QWlzJgn0HBAqXES4Z+vcjgD6frTJTvkjyMbl/EU1Cofg4x3x1qS90OLB13Jkgnrjnp6/hWZPkA+SCinqX9fUelXJ5tkZ3Kx3Ag+v4etRTEyIxzhQoPTnp2pSNKehlSh2wWz5aknHUGqUjbR5jlUJJAX1Hv7deauynZLGH2hipOSOAOvWqt+Y3yXULEnPoPw9RxWTO2BBCqSMj2w+UKeTwfp/KnT5RzIx+f1AyBiq1jeS3KF/s1xbQozALcII5HPrt54574Pt3q1IrOEYoWweFJxt9+KTKe5TulFwJGyIwp47du/8AnvUDxbnV+AikYC8fn+VSu6bsIC5Gct6e1ErEsse4EsBlcHP+TzUvU0irFGeMBmZ9uQ23GBxx+vWqlyjplEwwJyR/n0/pVySMyvhWOzOPvdcc5zVO4naTfgAjd3+lSbRV9DH8uO3gbz/mYrnn68cfnWZIxLZZgCcZBIravICNu+ckZ4xjj/IrD8gHJ29/7uaGaJI+bhZzH+HFOFhMf4a7OCxibYuEVyDjkkPzx9P/AK2K0otNiBfCR4Ixt25xxwMkdehrunmHL0PEWUUurZ56NOmPp+FPGlTld2OM46V6ZFpcDOC0abtuCNvGPb+easi1Qn5Qu4fKflHryOeuaxeZS6I0WVUOv5nlw0eXJHJI9Kl/skgAFTk989a9O+xQNtlEfBG7awAJPXPrmmJZpuZThxk4AHGe35DA/CoeZSNYZbh10POo9KZHIWMh+mOhoaCRcnBPFejC3UDCAKN2OvXnkVUbT4XyPLTa+Pl2dOvI9M/0pLHt7o3WEhFWirHn7B06qRUDz7d2QeK7e90qMKcJlkJyTwT09s9vfr71z1zpwEwTgsX2gDnPuK6qWJhM5quHnb3GZKzFmBRZDn2rpPDWmXlzerIw8hUOSSRlucY/nW3YaHaGCAqgfgEk9f8APP6V0ul2ggBjhTDgdNvTtzj8KiddT0S0IhSdtWaOnWaWmnxx28QQqOO5bHqT/WorOAyyMMkryAPT/JrRZgLdUwDuXHXgZ9BxVbTT5U5/eBX2/wAIyAf5d655bnpQVkdJpsZCRlmO5edrDOB7n05rat9yRtypbuMDkfU9e9VtP2i2Rj1bAYjnA/z2rRVAYo9oyqscZPT/ADzVGcmOQvmPKHco5APWrm4SDIQdecdRiq6kvNuySWGMbv1OanwBgktwxBGOnTp+FIjc0B8sRKgPxgCQ47eo6VZEbLEWjbHUKR8wBxVK1I8pgXb2BGQfpVtZJFQLGG5HC/hT0MJKzJI2k2oGfd0B4xk+lPLxyLgKq4GcnPP0qvHO5++FA657nmmsxBOBhSPlPpSuHLqTlWKfIQMdVJp0ZRApY4YtgjHbpUSs4IaMsPQ9M0sQcLlzvwTjIwKAL6OVQ5x5bcA9CPp3oidMNgjHcjpUMTHawb5s849KlYKmVVcKOTnjFMya6Fid9m3ag249B+lOh5A8s8kjkfhUCs21VZSRwMY69KnikCggoBjgDrTRDVkWVJQ5D8fpTkfJyMqR61CCS3P3SOfSpmXC8EBcY6dqpGbHRup3bxkYwMgf1pFjcszK3HcZ/wA4oglimcx7gzIeVHUenFWgFKY7dCc1SVyHKwseEJG4Z71LuUoCFBweccVWwvGMk54z6U9mITgkkcnnvTTM2iXYsgyxU47Unl7SQSAv16fgKhhfdyRjPfpmppIwQArbe5IIp7i2dhGIYvgjHQt3pxYAKSOF4qEOPNwQ24D0604srruLE4zlexpj5RjPknBZvwok5T7xAxk8VDGXEgUEgjrmk89A7LJkFugI/wA8Urmjj2GsjXEgyxUDA6dqSW3UuVDjb1wTT8Fny0m3jJOaciAEgHcccHP3falYpSaKc8eBsALEdGHXP4+lULsy7hsfJT73P5/yrVZRtcK5JXIJHGf8KyXMjSMkcW07AQCc+/41Mjem7lW3LSOWEI4OCTjAwP8APvT5UkVVwT5Z6lAP85pzKyKERB5jg7gAcc9aJXaPAm2h/u4H8sVFja+uhSeTcUYR4TbuIPU88VWuY55F2rJh+pz8wC9ce3U1ZCyKjbTjeAQTz9cCo7kPlFULuAyzAcAfyNS9jVNJ6EYDxFRIFEZxxwTkjtWfcln4RiHyAAP/ANdaMkAEbvJklDwF7f4elVlhGftGOmGQDrk/rUvYqLVyhIHUKpRmLkjcP8/Sqd6WSPyofnY54U9x3q/c5LK/IGe3X6E1l3DTCc+Wgbbld5xjApW0N1qUnWOSQLLtYxj+93yD+FKIxINyD5en3aURrEZZANzOAc9Sff8AlTTJk8MQOmMmpLZ46gyIwR5cu0cMMZOQefxzwOufbA07PeFfKlegI4Oe2eOfrWXGgiCxqI2Gc45PJ5AB9MCtK1O9V2AhSARyemMfp/nNc8yUklqPwTIgkAJBznoMfj7fzq0u3qO65JIwccmmHc20EjOeDQMKMKcAY+8OlZ33TLSuOZwM4Q8Efe4/HPemxlcsNg3/AJk9v8/jTWTduYlSTgnPQe5/Q9KYseFB3ZAODnnPB/z/AJyJZVrE7p8is3yrjI9B06n8ajfezNjO7OMFTz/n61OyHYWxxjB7df6VGm0tkkgrgAEdf84qnruHmEtsTH1Jzxxyc/y/yayLq0kZcqFXo5BGeefUfz9O1a5kGwcBsH0HA9T61XnYM+05CkZ7jH0/T/PFVGVnoYzj3LtjbhI06cfjnnvWvYZZtpk6+/X8cVR09Q1tGSBjGAQOa0bRfKdMtnI7dc+3rXeraHPBdy3LuBwq7u2B1Pt+lZcCj5g2EBOCWHzZHXjt3q9fl484zhl7jOaqR7VkAwd5XknufoOal2TudcdjqbW9+yxrG4U5Iw27J5H0rVgl3QqN5BVs89wTyPTt0965tLfz5YpMlpchimBg89a6KzhIiWKRCq9h1x7/AM6rqZySRcVTGT5gwCTxngHrU8ZZmQ4w/XBPp/8AqqNYtwBPJxU8UjHiQEsBtyF2846/yoM2aXmiNVZgUO3t70sMjPxz67QfTnJ9aqECaErI/wAp7rkHr61JaIPJy2dqHCkNn9aLmdkkX4n8vl1J6/SnBgzAtnIPGDiq7R/MPNPJOMCpUZUQFxlQdoOMf/roRm/IeoIlGVLem49OKmDHCu2TjOT1poAZPkPI9eOKfJu+U9c++M/40yWOS42qQMEZxjHWp0VmICZ9Bk96q2oJk3jAGeeatRhvMwh+YHpnkg/5FNeZEtNiwoIfY5wo5GetKVIb7pAzjIHtTF3RyfMQRnjjuasiRMsGXluM9vpTMnowCMQShBAPQ+lSqxiRjy+0ntzUduqgF0+YYwSD0qcqxTIwAeOev6VSIb6EkbJ5hfk7uScU84ZtysO/ao0XahDb2OfehQCeMr3xjnNUjIfbpvb17A+vt+tSAEEYXJ75pkS5f72BnJ9PyAqQShFOxd/1pqwne45T84AQle545qU5Z1+QkZGTxj86iikYrlhj6dqki+/9/gVRm+5CzoGaPkEdT2OfSqwdjII9p553Y6+tXpcEHuDnPtUJZFClcDHXjgUMuL0GHOWDbdo71H5qlCoAyByWGCM1N5REpfd8p5AHaklQIGkIBIOQSOvvSsyk0RpGS2VADYxnb0qFNyoSxwwHJHXNSfvc7iwUZ7EdPpUFxtZf3xwo6jHb1pFpXHl9+cY5+X3Jqm7lJVREV92BnHIwaeku/wDdxrjnOScDFQnLMu0hVB+9z/M1LZtFWIbhZTM/A2HAUFMbcdic81UktVgcvKWJxknj+X51edpFdMOpJ6Y5x7/5/pUDMDIxkJYcFR/n61DNoydjNETSMGUtjdgAn/PrU84MGVlw0h+9jknmnEFnaJD8w+mTzUMqvHKNkbN3yP4R6VBre7K80cihmYOA3AC9Px/zioI2lHZAhwACcnAHtVq5XeGJb5gR8i5x/niquGUtlvZQecVJotildT7SwjVjt4PH+e1UY/3kB3oAOWyOo9Pyq7qGYkVUjPzZyxGP881mRCSUnIaONUwVZcc5/wD10mmbxWg2aD+FYwq4Knn7uMVTZlDY2YxxhelX3l3qI7fg4HzAYGM8n9KqSb1chMBewA7VLZrbueOQo7IquSG28Lnrx97oOefX/wCtctB5K7RtxzgAc8+p6HtiqVpGk0UZSMiIjK+Zz6dj69Mf486cEZ8ssR369K5aj6EXViePbgMyg8krj+f6USliwAbcM446n8fwpyHC7Dyw5xjJHsakkRVOVGCASD69etQti0k1qVY4irYLMTjkYwBx0/8Ar1KjRHADZAH97H9ac4BUEq3UEEHHPvUIhOR+7A6jB79ev5D86XqO/QmUgkZOS3T3496YwAHB9DwMYqVkw+QFZxyPX8qhfcxxtGAOR6ccc9/wpu4b7EYQbmC4BOecDP0zVWcFFZlJduoGOP8A63T9KsyYHBU8DGOBx/LiqF1uD/IAuTtHAP8Akce/XFVFEyWhuaQ/2iFCR0JUcYz71u26BpSNwGRnOOwrlvD7/M0bRgLwfTICjjJ4z1rpLaU+YjA7lPUHj/P/ANeu+nK8UctrMs6htKEuSVPt2Hbis1IFMjTIwB+6BjBOf9n8Bz2x1rWdDIco4IkxtTA/w96zXZYd3no3GQGVmHtjND31N4vQ6bThGjoM7JDjAUg7vx/KugtXMgY9Dn15HpXI2EksiIB91lGxuFIYcAn+ddDYs0KRRE55+ZjTWhElobUKqjEqmGfkt/8AWqXyx5nLAZ79PyqgZXZiCctjHH+fSrCFiU5Yjv8ANke3FFzKzRdZcuFO1VwD8p/n/WpkXbhf4QR909TVRJFRGXI38MOeg9f51ZhG5d2/cx54P45oIlsSKN2cMPl6dqeCdgG0Akep5pX2opLHLnqQO/aiNeN2QwPU55oJv1ZLG8nlhVwV9SKemFJAxsxkZHemIMngqIyOhHWlVijYTO0ryBwaES9SwFy5ZQvIABz+tWkjKxl2OSOuO4qnGMLk5G3gf41bhd3ZTkFT6jmqMpXJZE3MnzBT1wD70pZQQCCw4yRjrUZJZxhcDOC2KsRFiVyS4PU46/4U7XMm7E0GEAGfXHt2qY4TI65x+NRgZ6D5SDndxUhjwd4OM8nnt6Va8jJ+ZLt2jjBBPboKC4Vh1yegqPkSkoOuc85pRkYyMD1Jp3JsSFSSC2cf3qiDMGxkdNpzxx7ZqZSGTBG0HoAe9KIxknbuJGD61VhXsRqrY2gZHrU0UgjiZVj49OtMZfnBBAOeRjk/WnKdoBc9fwpkvUY0gWDev3jxj37VXswWLPMrBgeMirY2qchfvdCaURgKCFHHb2oaKvZWCFwM4IJPAz1NLNgjaxG0DnnPekfBwU2jb2z61WlZEYENjB5yf0FPoKKuyK4kglUqhY92JOMeg+tZ8dypb7jAY27icgn6U+8lVUP2ZdpJz+P+NZ9uVEsSzylvm4Xv7Z9BmsHLU7adP3bs0YXjWSTyZFc7evbPvSTThwWULuPXk5PPpVG6mJf9zGvkDDgbsZNOtIRHboI3Dytzg8EHpk+nc079CvZ2XMxl0J1lkfgqF6e3se2KrLMtxIZBlynZTgD29TV97cmFVZlDHg9yfX+tUpwP3aRkcEDK4/OoloaQaasI8aeaWQlScZI6daC6eWTMm0dgB0x3zUwRmiLfKT0APc+uapTyECMkggnGV5qWUtRrSJBEWdSztjOOT+n0qBlYMGC4GcFX/WrRaMsMANwTw2ain8ySBvKBG5jjccY/z/OpehpF66mfdCRoCynLtgenA5NZ5lV2VVYcckHt/n+taF+JHAWJcgNnB6VWWFY4yAm5yew6H1/nSN42sZcpMkzqnyf7WMfWoExjl1zk9Rz1qa4Ro1WMbiASWwuMn6VWlESyMAcAHvSbsdG547as/k7VUtgkMTkkDGP556j/ABq/AXVuVbecLwB+pz/nmsmLAkBlifJyAFz1GeAejDAx6+9aULN53ybXXA5A6D0/p+HvxzVFYSRoWi4wzMMdOB/nnmpJDszI3OOeB369O9QZxG21nYAE/ID6njFSBSMqd27kk4yP8+1YpjWo4l2bIUjB6j6f/Xp0KgqQQ3uQfxpvBjOQ2TnORx09aVSwGQOGPPr+v1oQD5cbuvygZIAPB/H8fzqBivVlC552ng/Q4p285KnJUDuev+eajZ8hyc4HPp9f/wBVF9bhbqNkxtIwdy+mP1qjMGUIZATxjHHJ6469OoFXZCnCvkZzgZ6/5xmqd0VMC7g6nPyYyTn6/nVR3JZJpjgXSkeVhj1A+979B/kV0yKNpYYPfj14/wA/jXE2oZbmN0cFQVJZjnI5yPQ9/wAj6V10Ugf94pA46HuK7KWl0jCSSZsWzhkGzgnr6k9v/wBVUrxid24xEqMZyTjnp/Op7cl5FYjDZ5z6VDqUm2ZSki5bnB6DtnA/nWsmktRwNTSwg2xmXMoAVlUZ/wD19a37P5MhiwRh3XJArndNZIjGYzvcqPnKnd9K6G3jEoYA7lXLHI6fhTXkBoWzr5hITB6tzx/nFWBuWQMpwrN0z0qonyoGVOuMEY69s+tSiRjGWKAEHB74HHOaRDRoyKCgBQZI4x3647+9SWrlDvG1h78Yz/8ArqkhUyFg20Hk8dOKtIgBCk7CwzkcUiWtLFuJkYEZ4ByMc5NTB0AG05Pp6+1U4iynC4LA4Ge/TrVhpWXLbQMjjn3p9DNxJBKyYXsDxgVZVgrAjlunSoLcliNyqSPXj/PSrC/MWJxwcfLTM5WJ5QkkARtoweTnHNR2/wC7DI75U4JPTt0qUAKpcZJPT39KFCuAw3N32n1qvMy8i2ikMQAuz2POKmV1iOD2G7g81VXDLgZ34wBUwLqNpUbu2Tn+dNGTV9yeRg2f3uRx2pC8gjyG3cjnjkdhULRyGP5lwQc8HJqcqNoU5HPOBjBp7iskSJlW+Z+owNx6VLhHU7WBzngHNNjUJEPmJYdz19qkCMxJ7n5tx71SRk2MO5DjaCoONxOalDOWCp0xkHb09qiCvhicEjv3/GltjKrAFQwAxyc1SE9izCSyjEeOc80m4jHU544FKru3yoOeDzx/nrU0LAkA5zmq3M3oNhhJAG4nHTHHvRLtQ7Qeewx1pzBllJ3EDpillcFckbR0znp6U7IlNtlJoAfkO4gHJG7gVBPbxvIHdj8mMc/oK0NqRM7HcM/jj0FQvtwCQenXipaNoyfQyMxmdl3Aqo/ixwc9M1i6rEpLoWA3c5UYaQY4we3b3rSuLhIJJQwTywcHBwfqfT9f6VkyxLcMs6SOFLcB+gxWMn0PRoqzuMtJICgjNwyBVK55bdnscdT79sVcieVE2K4C7s7sYJGar2kCXOWWVi5OS3pge/Tirr2mMBmCgkBQO/rUpvcuo433EvZnfyxECyj7xHfpz7k1Ao8xh2Uchvz/ADpk5dCFWImPgbVYcY/z+tTwPznaw3cAdffj8u9Dd2TbljoJJFI0bMeADwOmKrmFBGU7E5znIBqzLP5rnYD3yc4I68fWqdw6pKC+BITn3X0/xqSo3FjtCo8zqQeSearzs2ZFyAM/if8ACrm6TZt24XHzKev/ANaq0mc91XovqRUuxcb3uVV81XwqKTnaM9F9T79f0qvIZBIwUb95Jz0/T/PFX5wPK2K5zk4wOe3+FZV4hEYVvmx0yfwzSub09StfzRoyhAWZiO2Ce3SssvGCQ1urN3OeprQcBQWCfOcAYxWQbyFCVKOSOM+tLQ2SsjyRYFlZhuGc7SdmOfpjGB+uavxDauAFYEccbc/p0z/OoFVkkyEX5uVVm4znk9Ppz0q55bBN4KbsYztxzmuOTb0Etdx6bUCjr2z379TUjMykAc5GCQcfXnv/AJ+tQRxmRwXZWIJ6Dvntn8atJHgE7sc8HNRqUrBvXzCuBkAEZ9P/ANYpI3baQu3ocnPemeWoGNo3Y47c/wAsf4U45Z+CQoJ4x2zzSRdglhPVsYGMY5x/nFQmNUPYInAx1461Zdjh1AGCMDjHOf0qu6q8mMBst8ylODz/AJ6UPcCG53ZJCfMPuhT09/yJqpNKh3KZByMEHnIx2/n071bndVJkc5ADcMOOO34VRmRXyYCmFXBbbuOfTHv7/wBK0gkS+7IpfkkQbvnHKAgKB6fXP5E+ldNZSFdrZJ464xk9/pzXGkDJUSbmUHCklSTk5yM85z7denr1Glyq9tAWG7ge2eK6Y+60jCaSN+zflTgmMntS3nFwrzBCowMN09PwpttlmBGFUEZPX/PerV7H5iIqMm5hyzAjB+vathxJbBN8WVALg5IAxgZHb6elb8PmMS2HAPII5PT/AD+lcpbSG0uYwCN2cbV9z/k10lvdg7dyttJKKQO/HBFMT1NZSu0eWec9xwy+1OT5BkRYUDJC/wCfpUMJ8xthxgkjjjvU2EiClgrORgHNIlllXXGdrFRzgdD/AJzVkMRsZuScYzkY46VTBzGMgANy2e+asRZd9w2bmwMdOP8AP8qQmiaFmMfzKM4Ix/8AXqym/YASMnvgfrUduwLKgBDZGc1NImxd6H5DjIzjrQZy3sPgYgYzwOhGcfj+OKtwTjfs2kqRncMZ/wA8VUZAY1b+FgWyD78CpEgV32gFQPmYsOc+tUjNpWNMSLtwATkjkdadFzwu7BOOlQHO1/MYEM2dw9aWJQZdwOxs8ZPFMw5dC3AHVMk5AOAO9Sl8LkLnBwVIqvK8ip8uTwBz1pYgHAwCDjPPUVVyGr6st+b5oYE7SBjjvRvZWCpgkHBwT1z/APXpixFsYBAwdrc5pUDBgWLewqiLKxbWMvGzOGYeg4p4Hlv9/jjgD+tVhK7DbnAzgjFTRMXOHA64yc9RVXM3F9R77ipwxBPoafEXzhmAwM8HmnCJVUgDOTnGab9nRsEjOCcfNnHvVW1IuiSMu0QUMN4Ygn1q1GGJJ2AehA7VUiLKNsafLnqB7VPE0jjBIxwQO5/zzVIzmhwDbiNxAB+8TUErxwqPnwOck0hJVTn5s981XvJEHy4XcVwe4I/yaLlQhd2JJrtBEGDbiVIP+TWPPIJny7kScgAHHHbinXAc5AAY5ADZ4AqIqiRlxuMmemQD7HvxWLdztp01Ez7+WMEItsIy20E5JD8c5/WhVt5FYlshVGAOp9B9fanzTpvUhcvkFQh9R3Pr64xTVDvJ80RUgBFOM8Y7eg681mzqWiQ60VmCmQoJCcgbcbcZ/wA/nU8sSJuECjep+UN0JqIW0ZnyS2CM5K4yPU1O0Lv/AB4Q+oyT/nmgiTV7ohtf9QTcBFfORjtj1qNJWmlCIny5O5h79qkkswx2su/qo56etKVzx5ZK9FVeOfapFdDVCbhCGwedpxz7/jUcdose9kj/AHh+8xHOfUVa8opklcvnB9h1x+dN2ujPI2CTwfTFIL9iiokMzq8uTkkD+769Kryx7pSn3gzfMoPUe5/CtOaENKGLqA2QCBjAx9aoFRA7gIpGCx2HnA749aTNYvsRSEjdtHReWYf57ZqpLtlLyKRjOM4H5/8A16fJIk0gixt/hGT97Hce1RzyKmIywULydx6/SkbxRQvwqx7UjZnK/JyBj61zsiJuO5cH610WozrnKYJ6ZBrCbT5pmMhZBknj0FCRsnZanl0L5mGxlYZO3ack+o9quKNpYsSVzxz2z6Z9az45EikzISwBAJI4Oecce+PzqwsmY2dsMvYluAPc1wyQRiy0shTkjo3H+I/nTt+MOVGOq4OM1CqF9oA56naM5Pp71OYkaNmI2kgHpyepxUmqWg0yZ25bAKjBzzUSAoSrEAoST14PU/4U2X5WOxRuIwCcj8M+nWnIWMW9uX/3cdvqf5/pUrRFMklkAYg8rj6YqB0xxkc9hwT249OnWmkB5XCvubGcZztHcg9uP89aEyxXYCegwe3Hbj+vpTSE9NhihgzM4EbZDHBJzx+H+RVWeQKoJzhmAG3HPGcZPbrVu4wwILBVOSMNxnHX9f5VlXzxBcAkknJbaAcYxkHH6etbU1dkPVlNnZJF3uUX7wB9R04zjqPXtXUaIRJbqdhAzgKfb/JrjZ2JBIYtkkdlAzjIwfX+X4103hSUtb7XGQvVc8j8PxrrlHZmU9djqbVl4IbODt69T7VeuIDc26EbH2njBIb/AD/9es23fbNnk8nJJ4xV6K7HmkADc3Jz/wDWpppqzFG/QrC1eSNkJWM7s5LYB49ev+e9aOiedFOs4LFVwvmDOAfqO+KS5jjO113FmOAegxVSC4nQ4UlvlxgL0Ge/Hv3osk7miO3iXcA7blOP73PHuKlUjbIYwDtIXI7H1rI0+5+YIpZgDxkYOD1rRZQEcYKEnOSO3b+lMya1LBHno2BhlO0hu4qYkjARd3Tg9MVHGMuN/YDIHp/nFWyNij5QvHAzzzSuJskJODldwz6Z9atWLxvJtc7XPBXPT/P9apnhVPlvkfdHvU0Y/fgPwV77e9NMzklYvS8HbGw+UkD0P+efyqwrs4Cso9ORwB+FUDI8bpjHlgjGe/PNXg4AUhCQvrTuZNWLMgAjYHt0Ip6BWjUKfmJ53cY4qNp1ZlwOQM4J/SnRszEn5ipOTxwOKfUxs7EsccqgbmUD6CrSGNk5Q57jHU0yFifM+7uAI47c46VKiAqd5+bp0xmqVuhnJu+pJbkAsuMEchf6VOsbSptDDAHft/hVaBcMrFgcE/KOvT/9VTkKRjOUJOfWquZS0YxYHClwWGD0U5H+NWynG5Qcg8gnAqrBwHWNieOT2Aq5EGj4kcOcYKgZOD/+qqiTJsj3ZlyR6DryKtABmCjIHrmmxwo6nK4YHG3PakdFTYN+GwT82SKpKxk2noMHDfINxI6dKmjR2IPQbR16Z9qrGNt2d+wZzx371IGbaWBDHPAzRcbQTnEmMA8Zx3J4/wDr1RvJjyDjAzwvJx6f5/GrL3H7xV2ngHJx8v51lancIJGmTcZOQvsR2/X/APVUTatob0YXaTIGuIeskuFPTgD5s/w+vf2FZ11IWux5YYoxJyjEEgg43c56/wD1qkVRNGzOhX5cllXBcjstNgtNm8rIxZz91+gwf881i3c9CKUSFkuRChjeMScLvz0HpntWpbI7qySt90k7iepqqLFAVkkeR1QhuRwh55Her0+JYdshYrnp0H/16a03IqSvohihY9wQsWzg5OT/APWqRFCriI/N0IJ4qOFHCDfGFRe2CMU+aYK7BoiQoOfT8TRcyeuiGySJFwiHzCcYBz+NOLEqoQbM9T0OPX+dRB4yMLkNnnHH+etMidSjyOpVg20E9+PrSvcaVi28ZjjyQSeuCcgd6qymXkBl2gDAqdWDr5u7ChuMHp/jVOdmfK5CsSBk8fjSY4K+5OyTMdpOB/FgHn8arXCBDuVRETjnoDj1zUkrFFzuBZVPUfh+feq+1872AJzngen+f0oZUUUZYoPMVt4TDHnJz6Ae9Z17FtUM2FA5AUdBnitOItLIcALGM846nPHP4VWu5wpZXUMmeApyTzzxU6HXFtaGNesBEmWMbHBPb/8AVVOZHaViJcA9iatPbyErK75Hcle3sahcuW+TZt7fSg2PH0gjUAqi7hwFAHb/ACalgSPcHXuu3sdoH4+9Rwq4jYTgBg38LFhgEdz+o781chj6ZGccg8/41wN2CMtFqSriNEAVh2BxgD8hQuOxwcAE/n2qOQgkHBVT1+lAVvmyxz1wRxk1FzVbBMisrDJxnr2/z/nikCjGN5YggE8bgffjFK42KxLHIGMnI4yPf0/nUSKwXDDoNpyCMe2e34UIY/A3LgA89z3Ht68VXkbY3zHJHvx3wM+vGfzqd8AE4ACjsOuP8mqodt43AkfKArgjJ56Hp/n64qKJYjzYUIFwVyMgAAegA+mKxrzcJTnAlBBYFRt529CefTIq9dGQBcFRtOcFgM45A559f55rJ1CQTMCR+9yAx7dB+XOfzrroQ1CxTmyyks5LMxYLjr7/AOfSuj8GzblljI247YAzXMHncQBkH8AK6HwbIyzyKG4C87vqf84711Vl7hg1qdiQglUqCJMfKOoGfSrdvIUBdsZP8OM4PSqgVnMZAGDz0z06/wBfzqygdiNuCR94fe/DFc60KS7luYotkJCZTk7UKr8p9eapEFBuTzU3cL5bYA/HrjrV7a7Ls3t5ac7Sen0zVC7Q4dCWXI4PI3En/wDVRJ2dzRK6OgsWxG0m8FgQpwwbORxwef0robJt8cbbcqBwV4xXHWDKWBL4ZlAwwycDj/PFdVpm9oB5bn5PfHHatLmc46GgdrFSVK7uzd/SnxsSQG6ZDZPJqPfkfvEAAPU9D71Yh2silyQcEDJOP/rUrmVtC2oKKEbkEZC4zzk+lSxnDfeABIPXk+1RmN2TeoypxzzwexP4VG+QW85eV6An/PqKLmbVy8oEiEdieoHQfSpkbBZWG/B+YdOCe9V4DG3IIXd3BwPY1YlDMSMA/LkZPUZp3Ia6DhtRctg4Gc55HPpVmGRj8gclcjH5Z6UyJQPMBAZgM88Zx2pNjKAwCgjoR/j3/wA9KbVjN2ehejeMyBpD8nTB45qSRwSFDYXrknH61VjzgrIFwCMsvIz06flViVFIAChmyPUcfWrTMWtSykv7tSgLkDPGDn3zVtcEZK5VhnZ3NVINqqQ2dh4G0gf57Vajjdo925kY/LwP0qkYzFWCMvkHaR0BHWrOCZs7i0XQDp+ZqOWIAhkLCRT1PcVEJXiYbyxU556jnvV6Iys5LQmDskxAwI8dMdfx/Kn3Em4RqME4yCBkZqsN7b2mx14GMgj3ouJJAojXHTqelO4KGqI1mXOViViDjdxS/aXeDEW4AZJLCsydphNsjGQPmYKce/FJLMywhMY3tgnrt+o56cH8ay5jq9khxLyiMTyAojBn9MAEjgdeO9Zc1wssht7dmbLFQy8HBPAA/wA+9XUkd3fcoz1+YgFgBjP0xVdLWcXCzQhIm378KBw3riod3sdEEk9S6VZwDPmSQjg7g20jqfcdfapkQNEX8wNn5QM/dxiq62TFR5g8vd1YZyfbrT1s1iUbnZcHd168U7szk47JkyOoZTCGA9c96rGVAPKZgTnPHHA/nUjBEBUs4PQnPIpn2eFkEi8tjaOe3+f5UmJWQ0yltiAOd2csg4BHrSy43eXIxfd93Hep4FVkVVyFUkAY5plzE8RAwCGGM7un0FILq9irMyIQDkKeoUZI/wA80u0TGKONCAT+Y96fsXbhVzg8859BSIVV12hgRngDrxSL6CFZFLJsLf7WcAfQ00RbYjvGWA65wcVOzlpSd4CgnqP8+9RG4RkkfkqemeMn3/KgE2QBPKhWSWQEEfMp7j0NQNJK0hWLgE4LDoO1XmjjeI7iAp7AdT6f59KrFxG7CBRgMOMDpQXF3K048sQoxGGGenWsi+XznWNTtc4+XuAOtbF6fMRHYgAjC8Yx+H+etUPKEZMxyznjORxxnp+VSzeDtqZU8bs2OkKD5U5GT71nyPH5jfKg57kg1sOdkZVvvZLc/T9Kz3NvIQ7IiswBI3e31pG6Z46j4CsjYO0fKRznvn/PY+tTxu5bCjHT6g9KzrdZFZcSr8x6sp69OPxwMfzq1HIyjYNzEYBYJ0wPQ/09q45RtsKPkWZBhSy8lsZO3jAyRTwuAA+FbjAPPT/OKSJ2kOCcc8MD978qsnCjazjkdB/Os2arsVmz8gVV4OCB6fX8qhlkwHPmYwDxtxk9h/8AWpZlMgdSzA45zkH2Pb2qJk/doZPMDHJJIPHoSM8dfbjjjpTikWkiITkvGjqhfJUkLjB9MH8v0olw2Q3yt0ALY5yTg8/5yetD4hkLhX6cnbwcDv0Hr61W+VpmEkjcDO4LkgDqfUcfzA6VqknqgcSC7OIlbLFsE53YIGAcDv0PXng+nTOmABLMQN4GS2TyRk+n1yPXvmrV46s7MjF1LbtpUce3vwB+X5ZZY43HAO7qc8+v+feu2lHQmS0K8nLYHAJ456VseEMPfkYUHbxnnv8A5/KsWQ8DIwD0J71p+EZANVC8nepUY7cfrW9Vfu2c9/eR6LyAGLjLfLk+vr/n2qZEaKZSQFwoypPHt/hUUU0aKhLIVPTj61YdW2na+epO3mvOOiKZfMh35QKW45I/nSyA+UzhUclSNuMZFV4lKfMm0AAKT0/T8amVvPj24IB6joTWl9LBGPREWmxbL0RtGruvQN046jjOP89K6rTGZYmZYRy3AGB1PbnoK4ySV7d5Gy3U4G7nH51vaJqCSOkYUqRgEnnp3z+IpQmvhHUjodQpGx3dVKAYyeP0pVk8shg+cHlc5zxRE37r5CCxODlenqKeYcynCYx0z3rQ57LZlqOZyTs+bGOSevWrsQwqmVQwIHvjPeqECllJQqGVTgDnj/OKmhl3hlDbflJGc5HOaaZnJdi0I085doHcDI9augxlQGB6dz+n6Vly7k2OcHgkFe3FWoDvRNsab1H8Qxn3600RKOhdkRWIjibHHHP9afbxEDzWYlhzxn+XHpUnkIVUblZx+JpWhkjYAMevc5wO1Ujnvpa5O0paI7tqkkcIKSOQsfLG45XPTge1QGI9HjB3ccDkH/PrT7WArK+4kf3efb/Cne7Iski9aOJEKcEodr455qzuZD5ZDKCMj3qG2XYh53KTliv8+amcl1iHyA4w3ritEc8txzCN2ySQRznv+lRySqp2s5z1II5x9aWEvsJYKTkkgDtn35qjd3K+cUm3oezevtTbshwhzOxajlTJMWTycAnGcetQ3N2L0MkIUOFLnsD9KyXug0hiUPGMn5yOOPeoLu5mliEUMbxyDAG1eDxznHXv+VZ8/Q6Vh9bl6EtLAjTSOCGwAjEgnuPr71CBDc3LtFNtjCn5GX5eOvTp1/Ssl52SErKzmYnACDOfT8cVPaiRLaFnYeWW464J7nPc+wzWfPc6HSa1uaNrFgYLF5EOckZz/j+VaLqwAkJGX6/KPX8qq2CxllacB2xlHJznNW3XzCrEAbTnIGAf8/0rRbHNUfvCurTIJC3ycjIPXnFVrm5EULy4LCMe/wDLqTVkhsfMx65JPc1GQRLgooO3AwM8e+Klu5ESKVFlUkqpwMk/5+tRNIWTbgCPOcEY/wD11c28bcBFHbqfSqzxvErOVUAcgDnvSZcWgUu6kq5QMpGcc4x/n9KB88QijP3f4s9B/Wi2n3R7iFyRnJP1/wAKW3mRioAJBOMnpx6e1IHcjjVmRljyeMAZ68en605BK6EAAMVAyR1PfNOwjSg5OT3xjNBO4qFJdBwc469gKaY2yqLdFJ3sxJJzk8CkuQFVVVV3nnB6elJJct5wjZGJPJY+npT2G+GN2LZcYA21PQ0V002IQnkq07ZcDLKBx05P61SadfOUeWQMbgeDkZHH6frVtj5f7pjlyQoP97jn8Kz2mRXCYUys2BgdPxoHBXHSyALIJMoBjnsDnpVESeZdCMfJEvJ+bHB9PyqyRsjxnJPCnp/+vtVZCY1Chc7toJPWg1itCrqJV9zIvPXAHA4/TvWCzEHCAKoAAGK07+cG5dQxDYHzMcc475+tZ7yvG20MuAB0qbnVFNKx49H5jRqGVWQnc3Y474GP88U+281mZ2GEY8lT15Hv0x/X2qK3VWAaJORwQGByB1wB6EkfhVu3iYDcNuQmQo4Hrya5pOwoeRZDhTgs2O2T27U95CVVVG0dATzj/IpkkYAG/aSMgA9OnAz/APWpfMRm2gvj1PT8/wA652axWhCZkzh1AJAB9+Ovv3454FMnOUfBHQjDdMnpxSO6KCzkBW+QE5PrjPtyeff35RsIXzlh1+Yn5eg6/wBPetEiyrcvLHJHFG7uhOZHHPAHPHXPTrVcP5yt+8w+0ELuJycHJHXAHJxjtx7TXcrB2LJtkIO4bRnGR7H0+nH0zlzSnKBUcoqqCxOeo4HTpzXVTjdAth19uiV+vmSnL49s56e/P5cmsh8gndgnrz/KrN1Irgnexctk5OR9f5//AFqoueOPzNd1KNkYSdkJM25Rzj6Ve8LyFdbgAIAOQc+mDWY7AdPpVvw4R/bEIORnI645wcc1pUX7qXocjmudHqUGQygJwx7DGB7mrzbgFXgZHTGO/wDh/ntWXak+aq7d0ZGS2Rhfbsee3+RWlG2GZy4Y+5zjv+PWvFvc9GJci+Wb5sBRjIK1INqkBEGD83B4NV7dwxUScL67v5e1TO6eZ8zMydOmB/npWqYWI9dtcQW8vmJJ5p3MIzh1x/e/pVe1uI4bmForcQZG1sZOSAOep+v41evYkNoejgYIHQg8Y6dqxFkLLGpYkoSSxO4txwDn8aio+V3RpFXidxpeoGRQxZlkDFQ3XtW3DKJQRxk9CCc4ridJmKAb5OACAuOGx3reiu41mJ8wqBwVJIIx3NbqV0Yzp66HUJI0Ukm8ABVI49fSpEiX5njcltuTjof92sNLxPLcOTnbgAHIGcYqfT7wMYwrjC4IXd1qro53Sa1NuEs8WVxtXg/Kc9fTP+c0udocBSMEDaOc89adZyrIBKrFgrYcEckdu1RXhiOJSQWBwcNn16Y5pmKjd2Nm1mDljlS2Bzjqac00ZwrNlR8wZT05rFt71Zbby02KynhuF498Dnr1pyy4OJX4zgL1Jz2Peq5kZui7m1bzea4AxtI4OcenAH/16lnWMv5TENk8c9v84rE8xlKGNmMQxltu0fSrUV2+QZMEbj90nCk549z0qlK+5m6TWqNWQG2ibYflwB8wxSW9wrRK5I3sOMe+MVjNqLSTlVG1SOQef8/WmWty5ma33rkAuykg8cZxRz66D+ru2u50QJ2j5/lIIAPUnPWsa+keZmCqzAg4wvUjsM1mXF7KAqJvJc8dgKsXd0m4M3ll+6sOR7/THXp170nNNWLp0HB3IPMjQkTxs4jXLIGAwemOnX2x2prXwYwraYKMh5bkhSehP4envTV82acukyxxBQPLA3HAzwpxwCewx1pbVUXy1RMburyDcxHrxwOewqGzp5V1JV04SzpNPuyRtYMcqT0BGO1aro0soQKChUIZdoAx6dOPw54qJZRbwbfKmcAklmJxz2/zzVyx2lPmLAY/i+vaqXY5qkpNcxLawhFCbAFI7nnHv6dKcqOmdrfJnjPPP1600t5ZG9mJPZeuTTigdRJJn1HJqmczu3djLhpidsWN2Qfm6H8KrxSzxSnzQGPQFTj+nHerpkRiVVvl6e5+lMV4sv8AMu844HP+eKm+o09LWK+6dmwybFPGBg8epzRM7ujKcEFerHBHt+lWlVRMF8xXLjnJwKgniKCTcFHvgHn/AA9qV7DTVytiMIGidCCct3z9PpThMvmMnzYOcMepx0FOhAg4yJSMkLjOTUcnlPhiQhyQDnkk0i7X0ZYyigM2Cey5yR9aqfaVfMiIyqPUdfwp00kcaYwFJbHOMZx1PrRGApUDgAcHGfp9Kd7gkkrsaoZ0QpwyAqFxj/J6VWUmEksc/wCyD+tSmU7crnG47u5aq+oFnKBCQBnc3Tcam63NYJ3sRQbXmclm81ueeg/GpI12yO6EnHXngdv8ajMifu40LKOdxHXHr9f8aGXEyrhtijJycY+v50ytypeOgZicHnnHGTzVI3DySncu1Mc57nt+FTzSm5kkIVRGDtGD1Hr+tVLmTfdeWP8AWNkYycYHf9KVzoSKl8VfzZUIUgBcdxjn9aoLHMwzuIJ7bRV64ltxEY1yCDvOf6mszzFf5jvG7nCjgfrSNNbHj1tJkBT8o/vHg55IPOeOvH8q0QZFYLlcbflTdwTx+nv/AJNa12yxZK7CFOYy3PHTJxn8/WrCZO4JGUOAd+Mkn6nt79v5YVHdjTRJNOVIXeBICCEHIIz+Pp/KmSyP5rL+8XaMjAByOnT23fpUNxIoCumdpOGHQ55wf06dKmWVUYO4ABHG3PI9xjGP5Vny21saxjpexGhlWTy8oOB7EjPUjHc5FSSMQoXaS6kcHDEEnAJ6f0qG6mJibIRD2BOMccfh+HtWcSjAtPHL5aqSCJN2Of8AH6dfxrSMObUajzasluAMLECrKCHIBxtXuSMAdu/rjBrKuMbQcfMcEE+3X61YmcFmO8MxXoFwOew/xx1qG425bPA5APUk478+1ddNcpfLZFGUEMeSSO+evvVZznJJzVqVlK5XIqm+d1dkDiraETkA+9TaTMYNSt3XjDjqeKhccfX2ptu226jbtkHGK1avFo4G7TXqetWkkrxoxGNyjhOMVdjZA7kA4OcZbge/51S06UTwI2MDG7GMg9O/+RWjKgmh/cq2/qccZH179K+bu7vyPZiu5MPmUDjYO47cdfpUsDs3+tT527A8Y/zj9KhjKxrsILFhjB5x0q7bg7MLhgRuBP8A+utotvqOw5kWRW5wuMMOn+f/AK9Zd7E8W0FVZ1yQQnqOh9a18sXbD4zwcdvrTZUWOEb0V8ggbhkgY/8Ar05xT1NIO2hjpPIwQKSGBOS+S36/j61ZS8mkkfcWJGRkMOcY4/rirK28UqKsXmGZT8wZMBgOQKmvfKLPJJCIy43qsQwoJPPHpWfvLW5qrXtYWzvDKPnlPHy/KenTFdHDIkCKA+7A+96dsj06/pXIrbmO2Yq7KSCMDgtwDgEfjzVlr0mJ1VgzMMZXoAPfPWtIz5V7xE6XM9DvdOu4IUP735GO45PU4/8Ar027vVCiJUZ0DAZ5yOPofSuU0m6ZZGYnBI25UZBBB7d+ozWhNfPsJmlCFsEcfw4PvWvOmjneHtI37ZCro/2c7XywYHGeMgD8hxVVr1fMZHZojjkuODn+vHtWfJqgEVxP5reeNpVVGFIAAGPf+lZkN6ZrsbmHzNghQdw6cc/Tj8aHJDjRerkdXFeyEuY2AhABCg9jxyPXJ/WtJb9fs6sVjUEYjA/vA9D2Pbt3rlXmW7uR9lgyADwDliAOR+me9SW9wWlSMfug0nyA5JGT7dqanymcsOnubN7HKoSVJCA4G4heMf5PSmTSi3vw6zkKq7C6Ahduc4Cj3569avafcNdxSo7M0mSm05bBHP8AjzWVewo+4Ha2BncP4eh+g/U+1DdiYavlkMubpkdZHkOQDyGwMevH49KsRqt3PCsrMrSMAWychT3x/n8aitliSBY7iCMEHh2OCf06fzrXit40tg4MqR9UwAoXtjPXNO9xzairF+ygWEGI4yhwGBySAPvZ9fc0v2eORS5QqhznJwc57YqSzjiSLDPljkjgYAHXPvVpW2lZAgwVGDjk/rV37nnyk03YiZ1VmDhwqjhWXIH4fTPemwMiOVCbe/T9PSk2PNjzCAg6Hp+tPhkVJBH8gIz8oB459fpSciWtCSSViMwjcM89wfxp4kwhOOOuCf0qVcsoyVB28k/5/pUcoZg4XhRli2eg9KbZlo9CB3iYrtbJPYHPfsfzqQFU3sy5OeNopJEwFTcCwBwT/P8AWnkGG3UbsjIBJ6HkZpXK7IYXRUdiW3E8EgnH+c1XnuGkkJkK4IzwD/Op5Y2c5jP7vGDj19MevvTEj3SnblQg7cc80io8q1IRLKCwSMgbey888+1RrEwY7jgjpz057VeiLrIVkXc7DP6nGfrUMUJy0m0ndubkjHX0oK5rFaSFZFBk+6MYGP5DuahvmZIxHEzDDAkjv6cVbjDLmSUrnjG0cAYqm8/+kF+Nqg4AGfzodi43ZKqEIqs2AmPxPrSXLBo8+WCQMYA6ehpbWLfMJGUqx6sOe3A+lR3pZEyQMnlhg/hRcEruxFiOKXYuW6nP4envSuQYXeWQlm6gHjpyKoSSSo++Rzvx93OAPSnvIZgsWwdMttOcf407mnI9ykqlGBRmZm6kenPNQXB8sSFQxcKTk9/wqxJnJIX92evPP1qjduRdoI1yoPz89Bz/APWpG6KtxzExKkbuOR7cfrms2RWhcxkY28Y2nj2rRuN5uQVDFVPI9TXM6nqTR30q4UYI43ew96NehWiPObMk2TOSS2wnJ65+SnX7FdGVlJDMm4kHqcx80UVl9pepJp+WnmKdi52oenfc9WXjRYyFRQAzYAHvRRXPM0WzKc3ykKOF8roOnGKpah8v2pRwobAA/wBwH+fNFFaU9y6fQzLh3CqQzZZtrHPUYXg+1Q3fEzAcDb/7LRRXZTLn+hmMSV5OeBVZ/wClFFd0DgrEcnaoE/18f+8KKK3jsefV+Jep6zpvy21sF4HlkcfjW9F/x5wnucZ9+cUUV80viZ78BvWNM/3c/wA6vWbEhQScY6fjRRThv8iupooBt6dx/Woo/mjYNyAmQD2OetFFbMUdzIl/49rlv4sZz75rUuFH2m1XA24Xjt900UVh9n7v/SmdP2EZtkzOQHYsCFyCc9jViIBI7goAp2HkcdjRRUL40X0JNG+a9kDchfug9uT0qe3+e3Rn+ZtxGTycYaiit47RMvtMpk4juMcZJB+mcVfc7BHs+XcvOOM9KKKUd1/XQuX9fgW4uNOLDhiFBPc5BzU+k86HOx+98nPfpRRWpjPd/I1ouGtwOhGD79KhidxphcMwYk5OeTRRSexzrct2ZPkWzZ+Ynk9zW5afPG+/5uB15ooq1sjGqWI+JbYDo2M+/NWg7BrbDEZTJwe+DRRWj2+Zw1dixKB9njGBgjkfjTCBtiGBjfjHtx/jRRQyI/qS2/zNGG5AB4P41MQPLmOBkEYPp1/wooqVuZMB/qpfbI/nUFx0j+goopyCO5JeHEBxx8q1BGSEcjg7m/8AQaKKcviQ4/CLL8hcp8p+bpx6VBbEm4ugScCRgPbrRRSfQvoyS94gmxxhMj261nSqv9nM20buTnHPQUUU5GlMfAzAcMR97v8ASqbE+STk5LjJ9eaKKl7GkfiGzqDC5IBO4c49qpz/AC3cu3jg9P8AdoooZstiZRvkj3/NwBzz2NZkoAjYgAERsQfTrRRTlsJbMxbp3Gm6iwZgy2rspzyDjqK+Zb69unu5We5nZi3UyEmiiujDfCcuYn//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tuberculoid lesion with a raised, well defined margin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James L Krahenbuhl, Phd and Robert R Jacobson, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35426=[""].join("\n");
var outline_f34_38_35426=null;
var title_f34_38_35427="Renal atheroembolus toluidine blue";
var content_f34_38_35427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal atheroembolus toluidine blue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thin section, toluidine blue stain shows the characteristic cholesterol clefts of an atheroembolus in the small renal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35427=[""].join("\n");
var outline_f34_38_35427=null;
var title_f34_38_35428="Bedbug bites in a group";
var content_f34_38_35428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bedbug bites - \"Breakfast, lunch, and dinner\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rows of hemorrhagic maculopapules are present on this patient with bedbug bites. The phrase, \"breakfast, lunch, and dinner\" has been used to describe this distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35428=[""].join("\n");
var outline_f34_38_35428=null;
var title_f34_38_35429="Levetiracetam: Patient drug information";
var content_f34_38_35429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levetiracetam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     see \"Levetiracetam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     see \"Levetiracetam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Keppra XR&reg;;",
"     </li>",
"     <li>",
"      Keppra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Levetiracetam&reg;;",
"     </li>",
"     <li>",
"      Ava-Levetiracetam;",
"     </li>",
"     <li>",
"      CO Levetiracetam;",
"     </li>",
"     <li>",
"      Dom-Levetiracetam;",
"     </li>",
"     <li>",
"      Keppra&reg;;",
"     </li>",
"     <li>",
"      PHL-Levetiracetam;",
"     </li>",
"     <li>",
"      PMS-Levetiracetam;",
"     </li>",
"     <li>",
"      PRO-Levetiracetam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levetiracetam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness or thoughts of taking your own life, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you. This often gets better after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10798 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35429=[""].join("\n");
var outline_f34_38_35429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187641\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187642\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025032\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025034\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025033\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025038\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025039\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025041\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025036\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025037\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025042\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025043\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=related_link\">",
"      Levetiracetam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=related_link\">",
"      Levetiracetam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_38_35430="Wrist blocks";
var content_f34_38_35430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Wrist blocks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 714px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wrist block anesthetizes any of the ulnar, median, or radial nerves at the level of the wrist to perform surgery of the hand or fingers. Only a small amount of local anesthetic is needed. Epinephrine should not be added to the anesthetic due to the potential for hand ischemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35430=[""].join("\n");
var outline_f34_38_35430=null;
var title_f34_38_35431="Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia";
var content_f34_38_35431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35431/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/38/35431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B-cell neoplasm small lymphocytic lymphoma (SLL), one of the indolent non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic features, diagnosis, and differential diagnosis of CLL will be reviewed here. The clinical manifestations, pathophysiology, molecular biology, cytogenetic abnormalities, and treatment of CLL are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24680?source=see_link\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a patient suspected of having CLL should include a complete blood count with differential, examination of the peripheral smear, and an immunophenotypic analysis of the circulating lymphocytes. While a bone marrow aspirate and biopsy and lymph node biopsy are not among the required elements of the diagnostic work-up, abnormalities seen on these examinations are included in this discussion of pathologic features. Chromosomal changes seen in CLL are also not diagnostic features of the disease and are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood smear of patients with CLL demonstrates a lymphocytosis. The leukemic cells are typically small, mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, and without discernible nucleoli. There is a narrow border of clear to slightly basophilic cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef54469 \" href=\"mobipreview.htm?22/17/22803\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a proportion of cells may be comprised of larger lymphocytes with large, somewhat notched nuclei, lacy appearing nuclear chromatin and visible nucleoli. These \"prolymphocytes\" usually account for a minority of the overall population of lymphocytes but can comprise up to 55 percent. The smear also often contains \"smudge\" cells that are lymphocytes that appear to have been flattened or smudged in the process of being spread on the glass slide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunophenotypic analysis, usually by flow cytometry, is a key component to the diagnosis of CLL (",
"    <a class=\"graphic graphic_figure graphicRef51190 \" href=\"mobipreview.htm?39/3/39991\">",
"     figure 1",
"    </a>",
"    ). While CLL lymphocytes are described as mature-appearing cells, they are, in fact, immature both functionally and developmentally. There are three major characteristic immunophenotypic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expression of B-cell associated antigens including CD19, CD20, and CD23. Expression of CD20 is usually weak. Expression of CD21 and CD24 can be seen, but is not required for diagnosis.",
"     </li>",
"     <li>",
"      Expression of CD5, a T-cell associated antigen.",
"     </li>",
"     <li>",
"      Low levels of surface membrane immunoglobulin (ie, SmIg weak). The immunoglobulin is most often IgM or both IgM and IgD, and only a single immunoglobulin light chain is expressed (ie, either kappa or lambda but not both), confirming the clonal nature of these cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, CLL cells are usually negative for cyclin D1 and CD10. FMC7, CD22, and CD79b are also commonly negative or weakly expressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bone marrow aspirate and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow aspirate and biopsy are not required for the diagnosis of CLL. If bone marrow biopsy and aspiration are performed at the time of initial diagnosis, they usually demonstrate normal to increased cellularity, with lymphocytes accounting for &gt;30 percent of all nucleated cells (",
"    <a class=\"graphic graphic_picture graphicRef63637 \" href=\"mobipreview.htm?24/1/24600\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to an increased percentage of mature-appearing lymphocytes in the smears of the bone marrow aspirate, there are three main types of infiltrative patterns of lymphocytes which are recognized in trephine biopsy specimens of the bone marrow: nodular, interstitial, and diffuse. Sometimes, in a given biopsy sample, one may see a mixture of nodular and interstitial, or nodular and diffuse infiltrative patterns. Patients with diffuse infiltration tend to have advanced disease and a poorer prognosis, whereas, for prognostic purposes, nodular and interstitial patterns may be grouped together in the prognostically better \"non-diffuse\" category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, with the discovery of additional prognostic markers in CLL, the prognostic value of bone marrow biopsy has become less clear. Prognostic markers in CLL are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15466?source=see_link\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As was noted above, CLL and small lymphocytic lymphoma (SLL) are considered to be the same disease at different points along a continuum. Historically, the diagnosis of SLL was made via a lymph node biopsy in a patient presenting with lymphadenopathy but without peripheral lymphocytosis, while CLL was diagnosed through examination of the peripheral blood and bone marrow in patients with lymphocytosis. Currently, the diagnosis of SLL is reserved for patients demonstrating lymph node pathology consistent with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    but with an absolute peripheral lymphocyte count that does not exceed",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    and no evidence of neutropenia, anemia, or thrombocytopenia related to the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathologic lymph node findings in SLL and CLL are identical and consist of a diffusely effaced nodal architecture with occasional residual naked germinal centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The infiltrate is composed of mostly mature-appearing, small lymphocytes, with an admixture of prolymphocytes and paraimmunoblasts (",
"    <a class=\"graphic graphic_picture graphicRef51681 \" href=\"mobipreview.htm?27/52/28486\">",
"     picture 3",
"    </a>",
"    ). The pathologic features on lymph node biopsy and the diagnosis of SLL are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CLL is based upon a complete blood count with differential, flow cytometry of the peripheral blood to determine the immunophenotype of circulating lymphocytes, and examination of the peripheral smear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To diagnose CLL, the 2008 update of the National Cancer Institute guidelines on the diagnosis and treatment of CLL concluded that the following two criteria must be met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute B lymphocyte count in the peripheral blood",
"      <span class=\"nowrap\">",
"       &ge;5000/microL",
"      </span>",
"      [5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L],",
"      </span>",
"      with a preponderant population of morphologically mature-appearing small lymphocytes.",
"     </li>",
"     <li>",
"      Demonstration of clonality of the circulating B lymphocytes by flow cytometry of the peripheral blood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/7\">",
"       7",
"      </a>",
"      ]. A majority of the population should express the following pattern of monoclonal B-cell markers: extremely low levels of SmIg and either kappa or lambda (but not both) light chains; expression of B-cell associated antigens (CD19, CD20, and CD23); and expression of the T-cell associated antigen CD5. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the current system, patients with an absolute lymphocyte count less than",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    are usually diagnosed with a monoclonal B lymphocytosis rather than CLL if they do not have palpably enlarged lymph nodes, spleen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver. The diagnosis of monoclonal B lymphocytosis is discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Monoclonal B-cell lymphocytosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As mentioned earlier, CLL and small lymphocytic lymphoma (SLL) have identical pathologic and immunophenotypic features and are therefore considered two ends of a spectrum of disease. Patients with lymphadenopathy without cytopenias and an absolute peripheral B lymphocyte count that is less than",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    are given the diagnosis of SLL rather than CLL. The diagnosis of SLL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the current diagnostic criteria, the diagnosis of CLL was based upon an absolute lymphocyte count (ALC) equal to or greater than",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    in the setting of an appropriate immunophenotype. With this system, patients with an absolute B lymphocyte count (B-ALC) less than",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    and an ALC more than",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    represented an overlap between CLL and monoclonal B-cell lymphocytosis. The switch to using B-ALC for the diagnosis of CLL in the current system eliminated this overlap, but has sparked controversy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the current definition uses a cutoff of 5000 B lymphocytes per microL, the ideal cutoff value is still to be determined. A retrospective analysis of 459 consecutive patients diagnosed with Rai stage 0 CLL over a seven year period at one institution found that cutoff values for ALC and B-ALC of 12,000 and 11,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    respectively, were predictive of reduced rates of treatment-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, a cutoff value of 5000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for either ALC or B-ALC was not predictive of outcome.",
"   </p>",
"   <p>",
"    This uncertainty about establishing the diagnosis of CLL does not alone affect the institution of chemotherapy, which is not started until the patient is symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CLL is suspected whenever the peripheral blood in an adult demonstrates an absolute lymphocytosis. However, blood lymphocytosis may also occur with non-neoplastic conditions, such as viral or other infections (eg, infectious mononucleosis, pertussis, toxoplasmosis) as well as in neoplastic conditions other than CLL (eg, the leukemic phase of lymphomas, hairy cell leukemia, prolymphocytic leukemia, and large granular cell lymphocyte leukemia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The task is therefore to distinguish between reactive causes of lymphocytosis and clonal (malignant) causes, and, for the latter, to distinguish CLL from the other malignant lymphoproliferative disorders. As described above, if the flow cytometric phenotypic features are consistent with the diagnosis of CLL in a patient with peripheral blood lymphocytosis, the diagnosis of CLL is clearly established. Features distinguishing these conditions with blood lymphocytosis from CLL are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infectious causes of lymphocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transient lymphocytosis can be seen in the peripheral blood of patients who have an infection. To be diagnosed with CLL, the lymphocytosis must be sustained over a period of time. This effectively excludes those conditions, such as infectious mononucleosis, pertussis, and toxoplasmosis, in which blood lymphocyte counts rise and then typically return to normal after a few weeks. In addition, unlike in CLL, a lymphocytosis does not occur in the bone marrow of patients with these infectious causes of lymphocytosis. Furthermore, the lymphocytosis is not clonal in those with a non-malignant cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monoclonal B-cell lymphocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term monoclonal B-cell lymphocytosis (MBL) is used to categorize individuals who have an absolute increase in the number of clonal B lymphocytes in the peripheral blood that does not exceed",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    [5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L]",
"    </span>",
"    and who have no lymphadenopathy, organomegaly, cytopenias, or disease-related symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Evaluation and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    MBL with a CLL-phenotype can be detected using high sensitivity flow cytometry in approximately 5 percent of patients over the age of 60 with normal blood counts and 14 percent of patients over age 60 with lymphocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ]. Patients with CLL-phenotype MBL progress to CLL requiring treatment at a rate of approximately 1 to 2 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. The rate of progression may be even lower among persons with low-count MBL, as defined as a clone size of",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best demonstrated in a prospective cohort study that followed 185 patients with CLL-phenotype MBL for a median of 6.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/11\">",
"     11",
"    </a>",
"    ]. Chromosomal analysis demonstrated that the CLL-phenotype lymphocytes in patients with MBL have the same genetic abnormalities as CLL cells, occurring at similar rates.",
"   </p>",
"   <p>",
"    Conversely, a monoclonal B-cell population appears to be present years prior to the diagnosis in virtually all patients with CLL. This was evaluated in a prospective analysis of lymphocytes obtained from the cryopreserved blood of 45 cancer-free subjects in whom CLL was subsequently diagnosed at a median interval of 32 months after collection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/18\">",
"     18",
"    </a>",
"    ]. A monoclonal B-cell population was identified by either flow cytometry or molecular analysis in 44 of 45 samples and none of 10 controls. Perhaps the most mystifying secret of all remains the reason why MBL occurs at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/19\">",
"     19",
"    </a>",
"    ]. Senescence, genetic factors and environmental factors need to be explored in future investigations.",
"   </p>",
"   <p>",
"    As only a small minority of these persons develop CLL it is important not to cause undue anxiety among them. We follow persons identified with MBL at yearly intervals with repeat flow cytometry of blood lymphocytes performed according to the physician's clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prolymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both prolymphocytic leukemia (PLL) and CLL can present with lymphocytosis and splenomegaly, and have circulating prolymphocytes in the blood. Prolymphocytes are both morphologically and immunophenotypically distinct from typical CLL cells. Compared with typical CLL cells, these are large cells with somewhat immature-appearing nuclear chromatin, a prominent vesicular nucleolus, and a moderate amount of cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef58721 \" href=\"mobipreview.htm?21/31/22001\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Prolymphocytes can be of either B or T lineage, express normal amounts of SmIg and do not express CD5. In contrast, typical CLL cells are of B lineage, express only low amounts of SmIg and express CD5.",
"   </p>",
"   <p>",
"    While prolymphocytes such as these can be seen in CLL, they typically comprise over 90 percent of the neoplastic cells in PLL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20358?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10102?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL) can have a leukemic phase that may mimic CLL. Such patients have circulating small lymphocytes with irregular or cleaved nuclei. Like the malignant cells of CLL, MCL tumors coexpress CD5 and CD20. However, the neoplastic cells of MCL stain strongly for cyclin D1 and surface membrane immunoglobulin (SmIg), have a t(11;14) chromosomal abnormality, and are negative for CD23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, the malignant cells in CLL are negative for cyclin D1 and are often CD23 positive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lymphoplasmacytic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both lymphoplasmacytic lymphoma (LPL) and CLL are lymphoproliferative disorders of small cells that usually have an indolent course. LPL is the lymphomatous counterpart to Waldenstrom disease (ie, LPL leukemia). Peripheral blood involvement in LPL is usually less prominent than in CLL; circulating malignant cells often have a plasmacytoid appearance (",
"    <a class=\"graphic graphic_picture graphicRef66365 \" href=\"mobipreview.htm?28/2/28708\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    LPL can be distinguished from CLL by its lack of CD23 expression, the presence of strong staining for surface IgM and CD20, and the presence of cytoplasmic Ig. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both hairy cell leukemia (HCL) and CLL can be associated with an elevated lymphocyte count in the peripheral blood. The diagnosis of HCL is often suspected based upon the presence of circulating lymphocytes with cytoplasmic projections (hairy cells) (",
"    <a class=\"graphic graphic_picture graphicRef81031 \" href=\"mobipreview.htm?41/56/42884\">",
"     picture 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35431/abstract/2\">",
"     2",
"    </a>",
"    ]. HCL is frequently distinguished from CLL based upon its immunophenotype that is usually CD5 and CD21 negative, and positive for CD25, CD11c, and CD103. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with follicular lymphoma (FL) can present in a similar fashion to those with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    with diffuse painless peripheral adenopathy, often waxing and waning over long periods of time. Usually, these two disorders have distinct growth patterns on lymph node biopsy. Follicular lymphoma has a nodular growth pattern which is not seen in",
"    <span class=\"nowrap\">",
"     CLL/SLL;",
"    </span>",
"    however, on occasion, involved lymph nodes in",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    tumors can have prominent proliferation centers that take on a mottled \"pseudo-nodular\" appearance that mimics that of FL.",
"   </p>",
"   <p>",
"    FL and",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    can be distinguished by immunophenotype. In contrast to the malignant cells in",
"    <span class=\"nowrap\">",
"     CLL/SLL,",
"    </span>",
"    most cells in FL demonstrate bright surface immunoglobulin (SmIg), express CD10 and lack CD5 expression. In contrast, CLL cells have extremely low levels of SmIg, express CD5, and lack CD10 expression. In addition, FL has a t(14;18) translocation which is not seen in",
"    <span class=\"nowrap\">",
"     CLL/SLL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Splenic marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both splenic marginal zone lymphoma (MZL) and CLL present with splenomegaly and peripheral blood lymphocytosis. In addition, both CLL and splenic MZL can express CD23, CD43, CD5, and IgD, although expression of these is much more typical of CLL. Unlike",
"    <span class=\"nowrap\">",
"     CLL/SLL,",
"    </span>",
"    MZL may have bright SmIg and CD20. In difficult cases, pathologic evaluation of the bone marrow, spleen, and hilar lymph nodes may be used in concert to determine the most likely diagnosis. Bone marrow morphology in MZL may show notched nuclei. In addition, cytogenetic changes typically seen in CLL are not usually seen with MZL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/39/12914?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm) characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. The disorder is considered to be identical (ie, one disease at different stages) to the mature B-cell neoplasm small lymphocytic lymphoma (SLL). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The peripheral blood smear demonstrates a lymphocytosis. The circulating leukemic cells typically resemble small, mature lymphocytes (",
"      <a class=\"graphic graphic_picture graphicRef54469 \" href=\"mobipreview.htm?22/17/22803\">",
"       picture 1",
"      </a>",
"      ), but a proportion of circulating cells may be comprised of prolymphocytes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Morphology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunophenotypic analysis reveals a clonal population of cells that express B-cell associated antigens (CD19, CD20, and CD23), the T-cell associated antigen CD5, and low levels of surface immunoglobulin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a bone marrow examination is performed at the time of initial diagnosis, it usually demonstrates normal to increased cellularity, with lymphocytes accounting for &gt;30 percent of all nucleated cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bone marrow aspirate and biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histopathologic lymph node findings in SLL and CLL are identical and consist of a diffusely effaced nodal architecture with an infiltrate composed of mostly mature-appearing, small lymphocytes, with an admixture of prolymphocytes and paraimmunoblasts. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lymph node biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CLL is made based upon the results of a complete blood count with differential and flow cytometry of the peripheral blood to determine the immunophenotype of circulating lymphocytes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of CLL includes both non-neoplastic and neoplastic conditions that result in a lymphocytosis in the peripheral blood. These include infectious causes of lymphocytosis, prolymphocytic leukemia, mantle cell leukemia, lymphoplasmacytic lymphoma, hairy cell leukemia, follicular lymphoma, splenic marginal zone lymphoma, and monoclonal B lymphocytosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/1\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. IARC Press: Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/3\">",
"      Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc 2007; 82:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/4\">",
"      Lipshutz MD, Mir R, Rai KR, Sawitsky A. Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia. Cancer 1980; 46:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/5\">",
"      Pangalis GA, Boussiotis VA, Kittas C. B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouv Rev Fr Hematol 1988; 30:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/6\">",
"      Rozman C, Montserrat E, Rodr&iacute;guez-Fern&aacute;ndez JM, et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/7\">",
"      Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/8\">",
"      Marti GE. The changing definition of CLL. Blood 2009; 113:4130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/9\">",
"      Hillmen, P, Cheson, BD, Catovsky, D, et al. Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al. Blood 2009; 113:6497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/10\">",
"      Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009; 113:4188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/11\">",
"      Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/12\">",
"      Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood 2012; 119:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/13\">",
"      Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009; 146:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/14\">",
"      Dagklis A, Fazi C, Sala C, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood 2009; 114:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/15\">",
"      Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 2009; 114:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/16\">",
"      Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009; 27:3959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/17\">",
"      Marti GE. MBL: mostly benign lymphocytes, but... Blood 2011; 118:6480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/18\">",
"      Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009; 360:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/19\">",
"      Vogt RF Jr, Kyle RA. The secret lives of monoclonal B cells. N Engl J Med 2009; 360:722.",
"     </a>",
"    </li>",
"    <li>",
"     Catovsky D, Foa R. The Lymphoid Leukaemias, Butterworths, London 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/21\">",
"      Stone RM. Prolymphocytic leukemia. Hematol Oncol Clin North Am 1990; 4:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35431/abstract/22\">",
"      DiRaimondo F, Albitar M, Huh Y, et al. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer 2002; 94:1721.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4513 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35431=[""].join("\n");
var outline_f34_38_35431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bone marrow aspirate and biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infectious causes of lymphocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monoclonal B-cell lymphocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4513|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/3/39991\" title=\"figure 1\">",
"      Flow CLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4513|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/17/22803\" title=\"picture 1\">",
"      CLL smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/1/24600\" title=\"picture 2\">",
"      CLL marrow low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/52/28486\" title=\"picture 3\">",
"      CLL lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/31/22001\" title=\"picture 4\">",
"      Prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/2/28708\" title=\"picture 5\">",
"      Lymphoplasmacytic cells in WM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/56/42884\" title=\"picture 6\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20358?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/39/12914?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_38_35432="Meloxicam: Drug information";
var content_f34_38_35432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meloxicam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/50/26405?source=see_link\">",
"    see \"Meloxicam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/18/2344?source=see_link\">",
"    see \"Meloxicam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mobic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Meloxicam&reg;;",
"     </li>",
"     <li>",
"      Auro-Meloxicam;",
"     </li>",
"     <li>",
"      Ava-Meloxicam;",
"     </li>",
"     <li>",
"      CO Meloxicam;",
"     </li>",
"     <li>",
"      Dom-Meloxicam;",
"     </li>",
"     <li>",
"      Mobicox&reg;;",
"     </li>",
"     <li>",
"      Mobic&reg;;",
"     </li>",
"     <li>",
"      Mylan-Meloxicam;",
"     </li>",
"     <li>",
"      Novo-Meloxicam;",
"     </li>",
"     <li>",
"      PHL-Meloxicam;",
"     </li>",
"     <li>",
"      PMS-Meloxicam;",
"     </li>",
"     <li>",
"      ratio-Meloxicam;",
"     </li>",
"     <li>",
"      Teva-Meloxicam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Osteoarthritis, rheumatoid arthritis:",
"     </b>",
"     Oral: Initial: 7.5 mg once daily; some patients may receive additional benefit from increasing dose to 15 mg once daily; maximum dose: 15 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F935401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/18/2344?source=see_link\">",
"      see \"Meloxicam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Oral: Children &ge;2 years: 0.125 mg/kg/day; maximum dose: 7.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F191894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No specific dosage recommendations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Significant impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;20 mL/minute): Patients with severe renal impairment have not been adequately studied; use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Maximum dose: 7.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F191895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Patients with severe hepatic impairment have not been adequately studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 7.5 mg/5 mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mobic&reg;: 7.5 mg/5 mL (100 mL) [contains sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 7.5 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mobic&reg;: 7.5 mg, 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes:",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088646.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088646.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9527178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without meals; take with food or milk to minimize gastrointestinal irritation. Oral suspension: Shake gently prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis (JIA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14080490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported in adult patients; abdominal pain, diarrhea, fever, headache, pyrexia, and vomiting were reported more commonly in pediatric patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 8%), pain (1% to 5%), dizziness (&le;4%), insomnia (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&le;2%), rash (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (4% to 10%), diarrhea (2% to 8%), nausea (2% to 7%), abdominal pain (2% to 5%), constipation (&le;3%), flatulence (&le;3%), vomiting (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&le;7%), micturition (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&le;5%), back pain (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (&le;8%), cough (&le;2%), pharyngitis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2% to 6%), falls (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abnormal dreams, abnormal vision, agranulocytosis, albuminuria, allergic reaction, alopecia, anaphylactoid reactions, angina, angioedema, anxiety, appetite increased, arrhythmia, asthma, bilirubinemia, bronchospasm, bullous eruption, BUN increased, cardiac failure, colitis, confusion, conjunctivitis, creatinine increased, dehydration, depression, diaphoresis, duodenal perforation, duodenal ulcer, dyspnea, edema (facial), eructation, erythema multiforme, esophagitis, exfoliative dermatitis, fatigue, fever, gastric perforation, gastric ulcer, gastritis, gastroesophageal reflux, gastrointestinal hemorrhage, GGT increased, hematemesis, hematuria, hepatic failure, hepatitis, hot flushes, hyper-/hypotension, interstitial nephritis, intestinal perforation, jaundice, leukopenia, malaise, melena, MI, mood alterations, nervousness, palpitation, pancreatitis, paresthesia, photosensitivity reaction, pruritus, purpura, renal failure, seizure, shock, somnolence, Stevens-Johnson syndrome, syncope, tachycardia, taste perversion, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transaminases increased, tremor, ulcerative stomatitis, urinary retention (acute), urticaria, vasculitis, vertigo, xerostomia, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, asthma, urticaria, allergic-type reactions) to meloxicam, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use within the first 10-14 days following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of  existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Oral suspension formulation may contain sorbitol. Concomitant use of sorbitol-containing products and  sodium polystyrene sulfonate (Kayexalate&reg;) may cause intestinal necrosis (including fatal cases); combined use should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F191921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Meloxicam may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Meloxicam may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Meloxicam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F191883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C /D &ge;30 weeks gestation (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies meloxicam as pregnancy category C (category D: &ge;30 weeks gestation). Meloxicam crosses the placenta. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Product labeling for Mobic&reg; specifically notes that use at &ge;30 weeks gestation should be avoided and therefore classifies meloxicam as pregnancy category D at this time. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F191898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F191873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether meloxicam is excreted in human milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F191874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food or milk to minimize gastrointestinal irritation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F191871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Meloxicam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg/5 mL (100 mL): $105.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Mobic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg/5 mL (100 mL): $167.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Meloxicam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $316.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $484.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mobic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $628.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $961.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F191862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC, serum chemistries, liver function, renal function (serum BUN and creatinine) with long-term use; signs and symptoms of bleeding",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aflamid (MX);",
"     </li>",
"     <li>",
"      Afloxx (PE);",
"     </li>",
"     <li>",
"      Arrox (HK, MY);",
"     </li>",
"     <li>",
"      Artriclox (CO);",
"     </li>",
"     <li>",
"      Atrocox (ID);",
"     </li>",
"     <li>",
"      Avegesic (MY);",
"     </li>",
"     <li>",
"      Cambic-15 (TH);",
"     </li>",
"     <li>",
"      Camrox (KP);",
"     </li>",
"     <li>",
"      Caxlem (PH);",
"     </li>",
"     <li>",
"      Coxicam (EC);",
"     </li>",
"     <li>",
"      Dormelox (BR);",
"     </li>",
"     <li>",
"      Ecax (CN);",
"     </li>",
"     <li>",
"      Exel (MX);",
"     </li>",
"     <li>",
"      Flamoxi (ID);",
"     </li>",
"     <li>",
"      Flodin (PE);",
"     </li>",
"     <li>",
"      Loxibest (MX);",
"     </li>",
"     <li>",
"      Loxil (ID);",
"     </li>",
"     <li>",
"      Mecaron (KP);",
"     </li>",
"     <li>",
"      Mecon (TW);",
"     </li>",
"     <li>",
"      Mecox (ID);",
"     </li>",
"     <li>",
"      Mel-OD (IN, MY, TH);",
"     </li>",
"     <li>",
"      Melart (PH);",
"     </li>",
"     <li>",
"      Melbrex (KP);",
"     </li>",
"     <li>",
"      Melcam (HK, TH);",
"     </li>",
"     <li>",
"      Melcox (KP);",
"     </li>",
"     <li>",
"      Melflam (HK);",
"     </li>",
"     <li>",
"      Melicam (TW);",
"     </li>",
"     <li>",
"      Melocam (AE, BH, CO, CY, EG, IL, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Melocox (KP, PH);",
"     </li>",
"     <li>",
"      Melodyn (AT);",
"     </li>",
"     <li>",
"      Meloflam (PH);",
"     </li>",
"     <li>",
"      Melosteral (MX);",
"     </li>",
"     <li>",
"      Melox (AE, BH, CY, EG, IL, IQ, IR, JO, KP, KW, LB, LY, MY, OM, QA, SA, SG, SY, TH, YE);",
"     </li>",
"     <li>",
"      Meloxibell (AU);",
"     </li>",
"     <li>",
"      Meloxin (ID);",
"     </li>",
"     <li>",
"      Memovic (KP);",
"     </li>",
"     <li>",
"      Merapiran (AR);",
"     </li>",
"     <li>",
"      Mevamox (BR);",
"     </li>",
"     <li>",
"      Mexpharm (ID);",
"     </li>",
"     <li>",
"      Mexx (PH);",
"     </li>",
"     <li>",
"      Miloxam (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Miovalis (AU);",
"     </li>",
"     <li>",
"      Mobec (DE);",
"     </li>",
"     <li>",
"      Mobex (KP);",
"     </li>",
"     <li>",
"      Mobic (AE, AR, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CI, CL, CO, CY, DK, EC, EG, ET, FI, FR, GB, GH, GM, GN, GY, HK, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NO, NZ, OM, PE, PH, PY, QA, SA, SC, SD, SE, SG, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Mobicox (CH, CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Mobiflex (ID);",
"     </li>",
"     <li>",
"      Mobix (PK);",
"     </li>",
"     <li>",
"      Movalis (BG, CZ, EE, ES, PL, PT, RU);",
"     </li>",
"     <li>",
"      Movi-Cox (ID);",
"     </li>",
"     <li>",
"      Movicox (NL);",
"     </li>",
"     <li>",
"      Moxalid (GR);",
"     </li>",
"     <li>",
"      Moxicam (AU, KP);",
"     </li>",
"     <li>",
"      Muvera (IN);",
"     </li>",
"     <li>",
"      Ostelox (ID);",
"     </li>",
"     <li>",
"      Paxicam (ID);",
"     </li>",
"     <li>",
"      Rafree (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~99%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C9 and CYP3A4 (minor); forms 4 metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 15-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Initial: 4-5 hours; Secondary: 12-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/38/35432/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10295 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35432=[""].join("\n");
var outline_f34_38_35432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709031\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191926\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191892\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F935401\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191893\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191894\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191895\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191849\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874886\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9527178\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191865\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080490\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191924\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191869\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191853\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191921\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191858\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191883\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191860\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191898\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191873\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191874\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191871\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191862\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869391\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191852\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191868\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10295|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/50/26405?source=related_link\">",
"      Meloxicam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/18/2344?source=related_link\">",
"      Meloxicam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_38_35433="Estrogen-associated migraine";
var content_f34_38_35433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Estrogen-associated migraine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Anne H Calhoun, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/38/35433/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/38/35433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decline in estrogen concentration is an important factor in triggering migraine in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/1\">",
"     1",
"    </a>",
"    ]. Estrogen-associated migraine refers to migraine headaches that occur when there is a decline in estrogen concentration after exposure to high levels of the hormone for several days (estrogen priming), as in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Natural declines in endogenous estrogen, such as at the beginning of the menstrual cycle (",
"      <a class=\"graphic graphic_figure graphicRef72415 \" href=\"mobipreview.htm?34/26/35246\">",
"       figure 1",
"      </a>",
"      ) or postpartum.",
"     </li>",
"     <li>",
"      Scheduled withdrawal from exogenous estrogen-containing products, such as during the hormone-free interval in users of cyclic estrogen-progestin contraceptives (pills, transdermal patch, ring) or with interruptions in estrogen therapy.",
"     </li>",
"     <li>",
"      Unintentional estrogen withdrawal, such as from missed doses of estrogen-containing drugs or as a result of drug interactions that reduce availability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Estrogen-associated migraine, primarily menstrual migraine, will be reviewed here. The pathophysiology, clinical manifestations and diagnosis of migraine and treatment of nonestrogen-withdrawal migraine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Headaches (including migraine) in pregnant women and use of estrogen-containing contraceptives in women with preexisting migraine headache are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5114?source=see_link\">",
"     \"Headache in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H40#H40\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Migraine headaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen has several important actions in the central nervous system that may account for its association with migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/4\">",
"     4",
"    </a>",
"    ]. The predominant effects are facilitation of the serotonergic and glutamatergic systems. Serotonergic tone in women is positively correlated with estrogen levels. When estrogen concentrations decline, serotonin concentrations also fall due to a decline in production coupled with an increased rate of elimination. The resultant decline in serotonergic function is associated with release of calcitonin gene-related peptide and substance P from trigeminal nerves, and may lead to vasodilation of cranial vessels and sensitization of meningeal afferents of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/5\">",
"     5",
"    </a>",
"    ]. Estrogen may also affect other chemical mediators, such as nitric oxide, magnesium, or prostaglandins, which may also modulate the balance between excitatory and inhibitory neurotransmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, it is important to remember that nonmigraine pain is also perceived as more intense perimenstrually, possibly reflecting changes in cranial nociception, as well as a decrease in endogenous opioid activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to puberty, migraine occurs in 2.5 to 4 percent of children, with a slightly higher prevalence among boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence changes with the onset of puberty, at which time migraine becomes markedly more prevalent in females than males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/10\">",
"     10",
"    </a>",
"    ]. This change has been attributed to hormonal fluctuations associated with pubertal maturation that precede the characteristic hormonal pattern observed in ovulatory women. This theory is supported by a study in which 25 percent of 9 to 12 year old girls referred to a pediatric headache center reported a monthly pattern to their headaches, even though only 13 percent had reached menarche [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Migraine is also very common in the perimenopausal period, which, like menarche, is characterized by marked fluctuations in estrogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Peak migraine prevalence in women occurs during the early 40s, and some studies suggest as many as 41 percent of all women will have experienced a migraine episode by age 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After menopause, the prevalence of migraine falls by about one-half, at least partly as a result of hormonal stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/10,14,16,17\">",
"     10,14,16,17",
"    </a>",
"    ]. It has been the author's observation that women who enter menopause with isolated menstrual migraine tend to improve, whereas those with menstrual migraine complicated by chronic daily headaches initially worsen. Clinical decline in this subgroup may be due, in part, to the impact of menopausal sleep disruptions on the headache disorder. Whether there is an association between menopausal symptoms and increased risk of migraine is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who undergo surgical menopause are thought to be more likely to experience worsening of their migraines than women who have natural menopause. Although observational data support this hypothesis, some data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/14,16,21,22\">",
"     14,16,21,22",
"    </a>",
"    ]. Patient selection may account for why some studies have found worsening migraine after surgical menopause. For example, one study only included women under treatment in headache clinics who underwent surgical menopause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/21\">",
"     21",
"    </a>",
"    ], and another included women with functioning ovaries in their surgical menopause group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/23\">",
"     23",
"    </a>",
"    ]. Women with endometriosis have a greater likelihood of chronic migraine (as opposed to episodic estrogen-withdrawal headache) and migraine disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/24\">",
"     24",
"    </a>",
"    ]. In my experience, these women are also prone to undergoing surgical menopause with the hope that it will relieve their chronic migraines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MENSTRUAL MIGRAINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pure menstrual migraine\" refers to migraine headaches that occur exclusively in close temporal relationship to menses, within a window spanning two days before onset through the third day of menstrual bleeding (day -2 to +3 of the menstrual cycle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/25\">",
"     25",
"    </a>",
"    ]. At least two-thirds of menstrual cycles in affected women should be associated with migraine. Women with \"menstrually related migraine\" experience other migraines in addition to their menstrual attacks. Menstrual migraine is exclusively migraine without aura.",
"   </p>",
"   <p>",
"    In this topic, the two types of menstrual migraine will be considered together. Compared with non-menstrual attacks, menstrual migraines tend to be more severe, last longer, and are less responsive to acute treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Neither type is commonly associated with aura, although affected individuals may experience aura with non-menstrual attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine may be the most common disabling condition in reproductive-age women, and menstruation may be the most potent and common of all migraine triggers. Up to 70 percent of female migraineurs report menstrual association. Pure menstrual migraine is less common than menstrually related migraine (7 to 21 percent of female migraineurs versus 35 to 56 percent of female migraineurs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of menstrual migraine are similar to those seen with nonestrogen-associated migraine; however, menstrual migraine is less commonly associated with aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/30\">",
"     30",
"    </a>",
"    ]. This is felt to be due to the relatively low estrogen environment associated with menses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link&amp;anchor=H21674085#H21674085\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of menstrual migraine should be the same as for migraine occurring at other times: a rapid-onset triptan administered early in the mild pain stage.",
"   </p>",
"   <p>",
"    If treatment of acute attacks is inadequate or unsatisfactory, then prevention is indicated. Factors to consider include medical comorbidities, side effects of individual agents, cost, and individual patient preferences. We suggest specific (hormonal) prevention with one of the following regimens: extended-cycle estrogen-progestin contraception, cyclic estrogen-progestin contraception with supplemental estrogen, or natural cycles with targeted supplemental estrogen. If contraindications to estrogen therapy exist, then nonhormonal strategies should be employed. Our preference is a long-acting triptan taken twice daily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion describes the evidence supporting these recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abortive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial abortive therapy of acute menstrual migraine is the same as for migraine occurring at any other time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440588\">",
"    <span class=\"h3\">",
"     Triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serotonin",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    agonists (triptans) are considered to be specific therapies for acute migraine because, in contrast to analgesics, they address the pathophysiologic mechanism of the headache. All triptans inhibit the release of vasoactive peptides, promote vasoconstriction, and block pain pathways in the brainstem. Triptans inhibit transmission in the trigeminal nucleus caudalis, thereby blocking afferent input to second order neurons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An advantage of triptans is that they have beneficial effects upon other phenomena of migraine, particularly nausea and photophobia. All of the triptans have been studied in randomized trials of the acute treatment of menstrual migraine; all were found superior to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440595\">",
"    <span class=\"h3\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonsteroidal antiinflammatory drug (NSAID) alone may be effective in some women. One randomized trial found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    (500 mg every eight hours as needed) was superior to placebo in treatment of acute menstrual migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/34\">",
"     34",
"    </a>",
"    ], and has the additional benefit of relieving dysmenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440610\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with a triptan and a NSAID is an option for women with both headache and menstrual symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preventive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the results of acute abortive therapy are incomplete or unsatisfactory, preventive strategies are indicated. Prevention includes lifestyle modifications (with or without pharmaceutical therapies) that are aimed at decreasing attack frequency, duration, accompanying symptoms, and disability. Preventive therapies for menstrual migraine can be either nonspecific (those that do not address the hormonal trigger) or specific (hormone-based treatments). With nonspecific strategies, success requires accurate anticipation of menses for scheduling interventions; therefore, women with irregular cycles are not good candidates for these options. Comorbidities (eg, dysmenorrhea, menorrhagia, endometriosis) and contraception needs may influence choice of preventive therapy or argue for their earlier initiation.",
"   </p>",
"   <p>",
"    Menstrual migraine appears to be a significant contributor to both chronic daily headache and medication overuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, preventive treatment has multiple benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only controlled trial of nonsteroidal antiinflammatory drugs (NSAIDs) for prevention of menstrual migraine found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    significantly reduced a composite pain index including frequency, severity, and duration of attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/38\">",
"     38",
"    </a>",
"    ]. Naproxen was given to 40 patients for three cycles at a dose of 550 mg twice daily beginning seven days before onset of menses and continued for 13 days. There is strong evidence that NSAIDs reduce dysmenorrhea, which is a common comorbid condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest benefit realized with this strategy should be balanced against the risk of potentially serious adverse events (gastrointestinal, cardiovascular) associated with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    and other NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .) The US Food and Drug Administration (FDA) recommends that patients should neither exceed the recommended doses for naproxen sodium (220 milligrams twice daily) nor take naproxen for longer than 10 days unless a physician directs otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scheduled dosing of triptans is effective for prevention of menstrual migraine; the most studied drug is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/55/9077?source=see_link\">",
"     frovatriptan",
"    </a>",
"    2.5 mg once or twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/39\">",
"     39",
"    </a>",
"    ]. The efficacy of scheduled dosing of triptans for prevention of menstrual migraine is based on data from four randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. In each of these trials, success was dependent upon the subject having regular menses and predictable timing of menstrual migraine. Scheduled doses were begun two days before the anticipated onset of menses and continued for five to six days.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial assigned 546 women with menstrually associated migraine to placebo,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/55/9077?source=see_link\">",
"       frovatriptan",
"      </a>",
"      2.5 mg daily, or frovatriptan 2.5 mg twice per day beginning two days before the anticipated onset of menstrual migraine and continuing for six days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/41\">",
"       41",
"      </a>",
"      ]. The incidence of menstrual migraine during three six-day perimenstrual periods was 67 percent for placebo, 52 percent for frovatriptan 2.5 mg daily, and 41 percent for frovatriptan 2.5 mg twice daily. Both frovatriptan regimens were significantly superior to placebo and the twice daily regimen was superior to the daily regimen.",
"      <br/>",
"      <br/>",
"      Another placebo-controlled randomized trial assigned 427 women with difficult to treat menstrual migraine to placebo, frovatriptan 2.5 mg daily, or frovatriptan 2.5 mg twice per day for three menstrual cycles beginning two days before the anticipated onset of menstrual migraine and continuing for six days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/42\">",
"       42",
"      </a>",
"      ]. The mean number of headache-free perimenstrual periods was 0.92 with frovatriptan 2.5 mg twice per day, 0.69 with frovatriptan 2.5 mg daily, and 0.42 with placebo. When migraine occurred, severity was reduced with both frovatriptan doses compared with placebo.",
"     </li>",
"     <li>",
"      A randomized, double-blind, placebo-controlled trial including 206 women reported",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/9/6293?source=see_link\">",
"       naratriptan",
"      </a>",
"      (1 mg twice daily beginning two days before anticipated menses and continued for five days) was effective for intermittent prophylaxis of menstrually associated migraine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients treated with naratriptan experienced twice as many headache-free perimenstrual periods than those on placebo (50 versus 25 percent). The drug was well tolerated and side-effects were comparable to placebo. For unexplained reasons, a higher dose of naratriptan (2.5 mg twice daily) was not significantly different from placebo.",
"      <br/>",
"     </li>",
"     <li>",
"      A randomized double-blind trial assigned 244 women with menstrual migraine to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      2.5 mg twice daily, zolmitriptan 2.5 mg three times daily, or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/43\">",
"       43",
"      </a>",
"      ]. Both zolmitriptan regimens were significantly more effective than placebo: the proportion of patients with &ge;50 percent reduction in headache frequency was 58.6 percent for zolmitriptan 2.5 mg three times daily, 54.7 percent for zolmitriptan 2.5 mg twice daily, and 37.8 percent for placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one small observational study, oral magnesium pyrrolidone carboxylic acid supplementation (120 mg three times per day, beginning on the 15th day of the cycle and continued until the next menses) reduced the number of days of menstrual migraine and improved menstrual complaints compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hormone-based interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with menstrual migraine appear to be particularly sensitive to physiologic declines in estrogen concentrations and stabilization of estrogen for a prolonged period of time appears to protect against migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, the goal of hormone-based prophylaxis is to eliminate or sufficiently minimize the premenstrual decline in estrogen that precipitates menstrual migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/46\">",
"     46",
"    </a>",
"    ]. A study of 229 women who were prescribed specific hormonal therapies for prevention of menstrual migraine found these strategies led to resolution of menstrually related symptoms in 81 percent of subjects who were compliant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hormonal prophylaxis can be an effective option for women who need contraception, women whose menstrual migraine does not respond to nonspecific approaches, and women with comorbidities that warrant its use. These conditions include endometriosis, menorrhagia, and dysmenorrhea, as well as women with irregular cycles for whom use of nonhormonal strategies are impractical.",
"   </p>",
"   <p>",
"    The use of estrogen-progestin contraceptives has been controversial in the setting of migraine with aura due to international studies that showed a small, but increased, risk of stroke associated with use of estrogen-progestin contraceptive pills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]; this was also shown in a systematic review of observational studies from outside the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, no US study since 1975 has found an increased risk of stroke associated with estrogen-progestin contraceptive pills. A large study from the United States reviewing 3.6 million women-years of use found no increased risk of stroke (OR = 0.96) with current low-dose estrogen-progestin contraceptive pills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/50\">",
"     50",
"    </a>",
"    ], nor did a pooled analysis of US studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discrepancy between US and international studies is possibly explained by the strong relative contraindication in the US to the use of estrogen-progestin contraceptive pills in smokers over the age of 35 (whereas the prevalence of smoking in most of the European case series was over 50 percent) and the more prevalent use of high-dose estrogen-progestin contraceptive pills in the international studies. These high dose pills accounted for the majority of stroke cases in the World Health Organization (WHO) study, but were used by only 0.7 percent of cases and controls in the pooled US studies.",
"   </p>",
"   <p>",
"    WHO concluded that the risks of estrogen-progestin contraceptives usually outweigh the benefits in women over age 35 with migraine and women of any age whose migraines are associated with aura (",
"    <a class=\"graphic graphic_table graphicRef62351 \" href=\"mobipreview.htm?36/61/37853\">",
"     table 1",
"    </a>",
"    ). The American College of Obstetricians and Gynecologists has stated that estrogen-progestin contraceptives may be considered for women with migraine headaches \"if they do not have focal neurologic signs, do not smoke, are otherwise healthy, and are younger than 35 years of age\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H10#H10\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H40#H40\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Migraine headaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adolescents with menstrual migraine, it is preferable to delay use of estrogen-progestin contraceptives until linear growth ceases, usually about two years after menarche. However, treatment benefits should be balanced with consequences of undertreatment of menstrual migraine, including missed school or work days, impaired performance, and possible progression to chronic daily headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42201?source=see_link\">",
"     \"Contraception: Overview of issues specific to adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of hormonal regimens has been proposed. Most studies were performed in women using oral estrogen-progestin contraceptive pills. It is likely that findings from these studies also apply to women using non-oral formulas, as well (vaginal ring, contraceptive patch). However, concerns have been raised about a possible excess risk of thromboembolism with the patch compared to oral contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=see_link\">",
"     \"Transdermal contraceptive patch\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22137996\">",
"    <span class=\"h4\">",
"     Extended-cycle estrogen-progestin contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional combined hormonal contraceptives used cyclically (ie, 21 to 24 active days and 4 to 7 non-hormone days) are unlikely to be beneficial in women who experience menstrual migraine in natural cycles. This is because the decline in estrogen during the four- to seven-day hormone-free interval is equivalent to the decline experienced in a natural cycle (ie, in a natural menstrual cycle, the late luteal phase decline in estradiol concentration is equivalent to that with cessation of use of a contraceptive pill containing 20 to 25 mcg ethinyl estradiol).",
"   </p>",
"   <p>",
"    Extended-cycle strategies involve continuous administration of an estrogen-progestin for an extended period of time and thus avoid a monthly abrupt decline in estrogen concentration. Several types of oral estrogen-progestin contraceptive pills are available for extended use and allow the woman to eliminate the hormone-free interval indefinitely. An open label uncontrolled study found that extended cycle dosing of an oral contraceptive was associated with improvement in mood scores, headache scores and pelvic pain compared to traditional",
"    <span class=\"nowrap\">",
"     21/7",
"    </span>",
"    cycle dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/53\">",
"     53",
"    </a>",
"    ]. Improvements persisted throughout the year of follow-up on extended-cycle dosing of an oral contraceptive containing drospirenone combined with 30 &mu;g ethinyl estradiol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=see_link\">",
"     \"Hormonal contraception for suppression of menstruation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-oral estrogen-progestin contraceptives (ring, patch) have also been used off-label in extended cycles. With prolonged suppression of ovulation, both menses and menstrual migraine can be avoided for months at a time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/54\">",
"     54",
"    </a>",
"    ]. The most common side effect of extended cycle regimens is breakthrough bleeding, but this tends to decrease over time.",
"   </p>",
"   <p>",
"    When using extended-cycle regimens that allow for periodic menses, we suggest estrogen supplementation in the otherwise hormone-free week (see below). If the decline in ethinyl estradiol dose is limited to 10 mcg, menstrual migraine can be prevented. LoSeasonique&trade; is a commercially available oral contraceptive that accomplishes this. It contains ethinyl estradiol 20",
"    <span class=\"nowrap\">",
"     mcg/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"      levonorgestrel",
"     </a>",
"    </span>",
"    for 12 weeks, followed by 10 mcg of ethinyl estradiol alone in week 13.",
"   </p>",
"   <p>",
"    If the patient is taking a 30 mcg extended cycle product, the addition of a daily dose of 20 mcg ethinyl estradiol during the scheduled non-hormone week may be beneficial in preventing menstrual migraine. This ethinyl estradiol dose can be approximated with conjugated equine estrogen 0.9 mg twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22138003\">",
"    <span class=\"h4\">",
"     Cyclic estrogen-progestin contraception with supplemental estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the late luteal phase decline in estradiol concentration in a natural menstrual cycle is equivalent to the decline in estrogen with cessation of use of a pill containing 20 to 25 mcg ethinyl estradiol. Therefore, cyclic use of estrogen-progestin pills containing &ge;20 to 25 mcg ethinyl estradiol does not prevent menstrual migraine, and higher dose oral contraceptives containing 30 to 50 mcg ethinyl estradiol would be expected to worsen menstrual migraine. For women who experience menstrual migraine, but want to use conventional estrogen-progestin contraception, the addition of supplemental estrogen during the hormone-free interval can prevent estrogen withdrawal migraine. As an example, a small open-label study administered a 20 mcg ethinyl estradiol oral contraceptive at bedtime on days 1 to 21, with 0.9 mg conjugated estrogens dosed at bedtime on days 22 to 28 (in lieu of the seven hormone-free pills in the pill pack) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/55\">",
"     55",
"    </a>",
"    ]. All of the patients had at least a 50 percent reduction in number of headache days per month, with a mean reduction of 78 percent.",
"   </p>",
"   <p>",
"    For women using a contraceptive patch, we suggest use of transdermal ethinyl estradiol 0.1",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours once weekly during the hormone-free week in women using the 20 mcg ethinyl",
"    <span class=\"nowrap\">",
"     estradiol/norelgestromin",
"    </span>",
"    contraceptive patch and transdermal ethinyl estradiol 0.075",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours once weekly for those using the 15 mcg ethinyl",
"    <span class=\"nowrap\">",
"     estradiol/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"      etonogestrel",
"     </a>",
"    </span>",
"    contraceptive patch. We have found these doses are usually adequate to prevent menstrual migraine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22138010\">",
"    <span class=\"h4\">",
"     Menstrually-targeted estrogen supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have contraindications to the use of estrogen-containing contraceptives may still be candidates for targeted strategies using low dose estrogen, such as perimenstrual transdermal administration of estradiol via a patch or gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/32,56-59\">",
"     32,56-59",
"    </a>",
"    ]. In one study, an estrogen patch was applied just before the onset of bleeding and left in place for seven days, thus limiting the magnitude of the premenstrual decline in estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/56\">",
"     56",
"    </a>",
"    ]. The 0.1",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours patch was effective; however, lower doses of estradiol (0.025 mg or 0.05 mg per 24 hours) did not prevent menstrual migraine. A randomized trial also found lower doses of transdermal estradiol (0.05 mg) are not effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/60\">",
"     60",
"    </a>",
"    ], while three studies reported estradiol gel 1.5 mg daily is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If estrogen supplementation is begun too early (starting six days before the first full day of menstruation and continued through day 2 of menses), there appears to be an increased risk of migraine just after the estrogen supplement is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22138017\">",
"    <span class=\"h4\">",
"     Selective estrogen receptor modulators&nbsp;(SERMs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one small open-label study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (10 to 20 mg per day for 7 to 14 days before menses and 5 to 10 mg for three days during menses) led to improvement in seven of eight women with severe migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/61\">",
"     61",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    has not been studied in menstrual migraine. There is insufficient evidence to recommend this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22138024\">",
"    <span class=\"h4\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies have shown a reduction in migraine with administration of GnRH agonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/48,62,63\">",
"     48,62,63",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     Leuprolide",
"    </a>",
"    acetate, administered intramuscularly for 10 months, markedly diminished menstrual migraine in women who had few headaches except for menstrual migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/62\">",
"     62",
"    </a>",
"    ]. During the last six months of the study, continuous estrogen and progestin therapy was added back in standard postmenopausal doses without exacerbation of migraine. Leuprolide was not beneficial in women with chronic daily headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GnRH agonists are not approved by the Food and Drug Administration for this indication and are generally not indicated for long-term use because of cost and side effects. The main side-effects of GnRH agonists are those induced by the hypoestrogenic state: vasomotor symptoms, insomnia, urogenital atrophy, and accelerated bone loss. Over 80 percent of women treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    for endometriosis report vasomotor symptoms, approximately 30 percent report vaginal symptoms (eg, vaginitis) and 30 percent report headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     \"Leuprolide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Progestin-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone is a potent GABA agonist and has an inhibitory effect on seizure generation, and likely an inhibitory effect on aura, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In women with migraine with aura unrelated to estrogen, progesterone-only contraception appears to decrease the frequency of attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/67\">",
"     67",
"    </a>",
"    ]. However, there is no evidence of any benefit of progestin-based therapies on menstrual migraine or hormonally-mediated headaches. In a seminal work that isolated the effects of estrogen and progesterone on menstrual migraine, Somerville showed that declines in estrogen precipitated menstrual migraine, while declines in progesterone had no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MIGRAINES AND MENOPAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perimenopause refers to the time immediately preceding menopause, marked by vasomotor symptoms and menstrual irregularities. Symptoms often begin four to seven years before menopause. During this transition, migraines typically worsen as menstrual cycles become erratic and closer together and sleep becomes disrupted.",
"   </p>",
"   <p>",
"    With menopause and the complete cessation of monthly cycling of estrogen, migraines usually improve. It is the author's clinical observation, from decades of experience in both menopause clinics and headache clinics, that if women enter menopause with episodic migraine, their headaches markedly improve. If they enter menopause with chronic daily headaches, they typically worsen, as the sleep and mood disruptions of menopause are superimposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EXOGENOUS HORMONE INDUCED HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous hormone induced headache refers to headaches that develop or worsen within three months of beginning use of exogenous hormones and that resolve or revert to baseline within three months of discontinuing exogenous hormones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/25\">",
"     25",
"    </a>",
"    ]. Other causes of new onset or worsening headache should be excluded, especially headaches with aura, which could represent transient ischemic attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies on the effect of estrogen replacement on migraine in menopausal women are heavily influenced by the regimen and women's baseline characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/69-71\">",
"     69-71",
"    </a>",
"    ] and currently provide little evidence-based guidance.",
"   </p>",
"   <p>",
"    The Women's Health Study found that the prevalence of migraine among 17,107 menopausal health professionals was 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/69\">",
"     69",
"    </a>",
"    ]. About 60 percent of these women were current users of hormone therapy, the rest were never users. Compared with never users, current users were more likely to have reported a migraine in the past year (odds ratio 1.42; 95% CI 1.24-1.62 after adjusting for confounders). However, it was not clear whether hormone therapy increased the risk of migraine or whether women with migraine were more likely to use hormone therapy, perhaps as treatment for their migraines. For women with a history of migraine, it could not be determined whether migraine frequency increased, decreased, or remained the same.",
"   </p>",
"   <p>",
"    The Postmenopausal",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Interventions Trial was a randomized placebo controlled trial that examined the effects of conjugated equine estrogen combined with three different progestogen regimens (two were cyclic and one was continuous) on selected outcomes in 875 postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/70\">",
"     70",
"    </a>",
"    ]. Curiously, women with no headaches at baseline tended to develop headaches on hormone therapy, whereas those with headaches at baseline tended to improve with this therapy; however, the type of headache (migraine versus nonmigraine) was not reported and whether subjects who worsened were on interrupted or continuous therapy (which would be expected to directly affect migraine expression) was not addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, treatment of migraine in menopausal women is the same as for migraine occurring at any time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the menopausal migraineur on estrogen therapy, we recommend continuous therapy to minimize or eliminate fluctuations in estrogen concentration. Cyclic hormone regimens, such as those in which estrogen is administered for only 25 days a month, are uncommonly used today and should be avoided in migraineurs to avoid an estrogen-withdrawal trigger. Data from a randomized trial showed that patients treated with a continuous combined estrogen-progestin regimen had fewer days with headache than those treated with cyclic or continuous sequential regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/71\">",
"     71",
"    </a>",
"    ]. Continuous therapy also increases the probability of induction of amenorrhea, which occurs in approximately 75 percent of women versus 10 to 20 percent with cyclic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40486?source=see_link\">",
"     \"Continuous postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also suggest using a transdermal or transvaginal estrogen product to minimize fluctuations in estrogen concentration. A randomized trial showed that patients receiving estrogen by the transdermal route had significantly fewer headaches and number of days with headache compared to those receiving oral estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/72\">",
"     72",
"    </a>",
"    ]. If an oral agent is used, we suggest bedtime dosing so that trough estrogen levels do not occur during the early morning hours, which is the peak time of migraine occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progestogens include both progesterone and synthetic progestins. When needed, they may be given either continuously or cyclically without impacting migraine frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/69,74\">",
"     69,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EXOGENOUS ESTROGEN WITHDRAWAL HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen-withdrawal migraine is defined as a migraine that occurs upon interruption of daily use of exogenous estrogen for &ge;3 weeks, within 5 days of the last use of the estrogen product, and resolves within 3 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This occurs most commonly during use of cyclic estrogen-progestin contraceptives or cyclic estrogen therapy, but can also be related to an unintentional decline in estrogen concentration, such as from missed doses of estrogen-containing medications or drug interactions that result in accelerated metabolism of oral estrogens.",
"   </p>",
"   <p>",
"    Short-term administration of a gonadotropin-releasing hormone analog, which inhibits gonadotropin secretion, acutely suppresses ovarian steroidogenesis and thus can precipitate estrogen withdrawal migraine attacks. This has been reported during the downregulation stage of in vitro fertilization when 17-beta-estradiol falls to a very low level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/75\">",
"     75",
"    </a>",
"    ]. On the other hand, continuous administration of a gonadotropin-releasing hormone analog during treatment of endometriosis results in prolonged suppression of estradiol and is associated with improvement in pure menstrual migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], but not in menstrual migraine complicated by chronic daily headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment to abort an acute estrogen-withdrawal migraine is the same as for migraine occurring at any time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute treatment of migraine in adults\", section on 'Abortive therapy plus parenteral dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When acute therapy is ineffective, prevention may be indicated. Since these headaches are precipitated by estrogen withdrawal (scheduled or accidental), prevention is aimed at eliminating this trigger or reducing the occurrence of fluctuations in estrogen levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440633\">",
"    <span class=\"h3\">",
"     Bedtime administration of estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral estrogen should be administered in the evening. This prevents even a small nadir in estrogen concentration during the morning hours or critical sleep stages, when the threshold for migraine occurrence is lowest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440641\">",
"    <span class=\"h3\">",
"     Transdermal or vaginal ring preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoral estrogen preparations are preferable in some patients, including smokers, women who frequently forget doses, and those whose concomitant medications (eg, antiepileptics, antidepressants, antibiotics) may induce cytochrome p450 3A4, leading to more rapid degradation of oral estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/38/35433/abstract/73\">",
"     73",
"    </a>",
"    ]. All of these scenarios produce gaps or instability in estrogen concentration, which could exacerbate migraine. Transdermal and vaginal ring delivery systems result in more constant hormone levels than oral preparations.",
"    <br/>",
"    <br/>",
"    Women using patch or ring therapy should be questioned about any increase in headaches immediately preceding patch or ring changes, which suggests the need to shorten the interval between these changes. Reported changes in headache frequency should always be confirmed by reviewing the patient's headache calendar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440649\">",
"    <span class=\"h3\">",
"     Lowest dose estrogen-progestin contraceptive pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a woman experiences migraine only when using a cyclic mid- to higher-dose estrogen-progestin contraceptive pill (30 to 50 mcgs), then changing her to a lower estrogen dose product (20 or 25 mcgs) may be helpful since the fall in estradiol during the hormone-free pill week will be less (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Hormone-based interventions'",
"    </a>",
"    above). Even lower dose options are now available, including a ring contraceptive that contains 15 mcg ethinyl estradiol and a pill that contains 10 mcg ethinyl estradiol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4440657\">",
"    <span class=\"h3\">",
"     Extended-cycle estrogen-progestin contraceptive pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extending the period of active hormone use reduces the number of times the woman experiences estrogen withdrawal and thus should reduce the frequency of estrogen withdrawal migraine (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Hormone-based interventions'",
"    </a>",
"    above). Strategies to prevent the estrogen withdrawal migraine in the menstrual week of these products are discussed above, under Cyclic estrogen-progestin contraception with supplemental estrogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decline in estrogen concentration after significant exposure to estrogen is a trigger for migraine in some women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Menstrual migraine and menstrually related migraine refer to migraine headaches that occur in close temporal relationship to menses, typically two days before onset through the third day of menstrual bleeding. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Menstrual migraine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial abortive treatment of acute menstrual migraine is the same as for migraine occurring at any other time. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Abortive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors to consider in choosing preventive treatment include medical comorbidities, side effects of individual agents, cost, and individual patient preferences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with menstrual migraine who need contraception, women whose menstrual migraine does not respond to nonspecific approaches, and women with menstrual migraine and comorbidities that warrant use of estrogen, we suggest estrogen-based therapy rather than a triptan (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our initial approach is to use estrogen-progestin contraceptive pills in an extended cycle; our second choice is menstrually-targeted supplemental estrogen. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hormone-based interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If contraindications to estrogen therapy exist or the woman chooses to avoid estrogen, we suggest nonhormonal strategies using long-acting triptans dosed twice daily beginning two days before anticipated menses and continued for five days. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Preventive therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exogenous hormone induced migraine refers to migraine headaches that develop or worsen within three months of beginning use of exogenous hormones and that resolve or revert to baseline within three months of discontinuing exogenous hormones. For women who develop headaches related to use of exogenous oral estrogen therapy, we suggest continuous transdermal or vaginal administration of estrogen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Exogenous hormone induced headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Declines in exogenously administered estrogen can precipitate migraine. These can occur with scheduled withdrawals from exogenous hormonal products or with unintentional estrogen withdrawal, such as from missed doses of estrogen or drug interactions that result in declines in estrogen concentrations. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Exogenous estrogen withdrawal headache'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/1\">",
"      Scharff L, Turk DC, Marcus DA. Triggers of headache episodes and coping responses of headache diagnostic groups. Headache 1995; 35:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/2\">",
"      Somerville BW. Estrogen-withdrawal migraine. II. Attempted prophylaxis by continuous estradiol administration. Neurology 1975; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/3\">",
"      Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/4\">",
"      Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part I. Headache 2006; 46:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/5\">",
"      Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/6\">",
"      Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part 2. Headache 2006; 46:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/7\">",
"      Hellstr&ouml;m B, Anderberg UM. Pain perception across the menstrual cycle phases in women with chronic pain. Percept Mot Skills 2003; 96:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/8\">",
"      D'Amico JF, Greendale GA, Lu JK, Judd HL. Induction of hypothalamic opioid activity with transdermal estradiol administration in postmenopausal women. Fertil Steril 1991; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/9\">",
"      BILLE BS. Migraine in school children. A study of the incidence and short-term prognosis, and a clinical, psychological and electroencephalographic comparison between children with migraine and matched controls. Acta Paediatr Suppl 1962; 136:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/10\">",
"      Waters WE, O'Connor PJ. Epidemiology of headache and migraine in women. J Neurol Neurosurg Psychiatry 1971; 34:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/11\">",
"      Crawford MJ, Lehman L, Slater S, et al. Menstrual migraine in adolescents. Headache 2009; 49:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/12\">",
"      Miro F, Parker SW, Aspinall LJ, et al. Sequential classification of endocrine stages during reproductive aging in women: the FREEDOM study. Menopause 2005; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/13\">",
"      MacGregor EA. Migraine headache in perimenopausal and menopausal women. Curr Pain Headache Rep 2009; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/14\">",
"      Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993; 17:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/15\">",
"      Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999; 53:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/16\">",
"      Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache 2003; 43:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/17\">",
"      Freeman EW, Sammel MD, Lin H, et al. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008; 111:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/18\">",
"      Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric 2000; 3:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/19\">",
"      Sabia S, Fournier A, Mesrine S, et al. Risk factors for onset of menopausal symptoms: results from a large cohort study. Maturitas 2008; 60:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/20\">",
"      Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache 2003; 43:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/21\">",
"      Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993; 33:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/22\">",
"      Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993; 168:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/23\">",
"      Calhoun AH. Migraine and menopause. Headache 2004; 44:106; author reply 106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/24\">",
"      Tietjen GE, Bushnell CD, Herial NA, et al. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache 2007; 47:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/25\">",
"      Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalagia 2004; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/26\">",
"      MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004; 63:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/27\">",
"      Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003; 23:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/28\">",
"      Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/29\">",
"      Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000; 55:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/30\">",
"      Johannes CB, Linet MS, Stewart WF, et al. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology 1995; 45:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/31\">",
"      Ashkenazi A, Silberstein S. Menstrual migraine: a review of hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother 2007; 8:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/32\">",
"      Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008; 70:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/33\">",
"      Marcus DA, Bernstein CD, Sullivan EA, Rudy TE. Perimenstrual eletriptan prevents menstrual migraine: an open-label study. Headache 2010; 50:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/34\">",
"      Al-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res 2000; 5:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/35\">",
"      Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009; 114:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/36\">",
"      Cady RK, Diamond ML, Diamond MP, et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache 2011; 51:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/37\">",
"      Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache 2008; 48:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/38\">",
"      Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/39\">",
"      Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/40\">",
"      Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001; 41:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/41\">",
"      Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/42\">",
"      Brandes JL, Poole Ac, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009; 29:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/43\">",
"      Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs 2008; 22:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/44\">",
"      Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/45\">",
"      Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA 2006; 295:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/46\">",
"      Calhoun, A. Four hypotheses for understanding menstrual migraine. The Female Patient 2004; 29:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/47\">",
"      Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/48\">",
"      Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004; 164:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/49\">",
"      Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/50\">",
"      Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/51\">",
"      Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998; 29:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/52\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/53\">",
"      Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/54\">",
"      Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/55\">",
"      Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J 2004; 97:819.",
"     </a>",
"    </li>",
"    <li>",
"     Predalier, A, Vincent, D, Beaulieu, PH, et al. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: New advances in headache research, Rose, FC, (Ed), 4th ed, Smith-Gordon, London 1994. p. 129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/57\">",
"      de Ligni&egrave;res B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed) 1986; 293:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/58\">",
"      Dennerstein L, Morse C, Burrows G, et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/59\">",
"      MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006; 67:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/60\">",
"      Alm&eacute;n-Christensson A, Hammar M, Lindh-&Aring;strand L, et al. Prevention of menstrual migraine with perimenstrual transdermal 17-&beta;-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril 2011; 96:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/61\">",
"      O'Dea JP, Davis EH. Tamoxifen in the treatment of menstrual migraine. Neurology 1990; 40:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/62\">",
"      Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and \"add-back\" therapy. Fertil Steril 1997; 67:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/63\">",
"      Lichten, EM, Lichten J, Whitty, A, Peiper, D. The use of leuprolide acetate in the diagnosis and treatment of menstrual migraine: The role of artificially induced menopause. Headache Q 1995; 6:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/64\">",
"      Martin V, Wernke S, Mandell K, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 2003; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/65\">",
"      Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril 1990; 54:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/66\">",
"      Finocchi C, Ferrari M. Female reproductive steroids and neuronal excitability. Neurol Sci 2011; 32 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/67\">",
"      Nappi RE, Sances G, Allais G, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception 2011; 83:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/68\">",
"      Somerville BW. The role of progesterone in menstrual migraine. Neurology 1971; 21:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/69\">",
"      Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt) 2003; 12:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/70\">",
"      Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998; 92:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/71\">",
"      Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache 2002; 42:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/72\">",
"      Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38:157.",
"     </a>",
"    </li>",
"    <li>",
"     Calhoun, AH. Women's Issues in Headache. In: Headache, Loder, E, (Ed), American College of Physicians, American Society of Internal Medicine 2004. p 157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/74\">",
"      Nand SL, Webster MA, Baber R, Heller GZ. Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group. Climacteric 1998; 1:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/38/35433/abstract/75\">",
"      Amir BY, Yaacov B, Guy B, et al. Headaches in women undergoing in vitro fertilization and embryo-transfer treatment. Headache 2005; 45:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5441 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D4E9CFABE8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35433=[""].join("\n");
var outline_f34_38_35433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MENSTRUAL MIGRAINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abortive treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440588\">",
"      - Triptans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440595\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440610\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preventive therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Triptans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Magnesium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hormone-based interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22137996\">",
"      Extended-cycle estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22138003\">",
"      Cyclic estrogen-progestin contraception with supplemental estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22138010\">",
"      Menstrually-targeted estrogen supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22138017\">",
"      Selective estrogen receptor modulators&nbsp;(SERMs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22138024\">",
"      GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Progestin-based",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MIGRAINES AND MENOPAUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EXOGENOUS HORMONE INDUCED HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EXOGENOUS ESTROGEN WITHDRAWAL HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440633\">",
"      - Bedtime administration of estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440641\">",
"      - Transdermal or vaginal ring preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440649\">",
"      - Lowest dose estrogen-progestin contraceptive pills",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4440657\">",
"      - Extended-cycle estrogen-progestin contraceptive pills",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5441|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/26/35246\" title=\"figure 1\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/61/37853\" title=\"table 1\">",
"      WHO MEC for neurologic conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40486?source=related_link\">",
"      Continuous postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42201?source=related_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5114?source=related_link\">",
"      Headache in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=related_link\">",
"      Leuprolide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=related_link\">",
"      Transdermal contraceptive patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_38_35434="Cafe-au-lait macule";
var content_f34_38_35434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57807%7EDERM%2F73651%7EDERM%2F50599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57807%7EDERM%2F73651%7EDERM%2F50599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large caf&eacute;-au-lait macule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large caf&eacute;-au-lait macule on the flank of a young child with neurofibromatosis type 1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Yale Dermatology Residents' Slide Collection.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Caf&eacute; au lait macules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple caf&eacute; au lait macules were present on this young boy with neurofibromatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Caf&eacute; au lait macule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This uniformly tan patch is a caf&eacute; au lait macule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smeltzer SC, Bare BG. Textbook of Medical-Surgical Nursing, 9th ed., Lippincott Williams &amp; Wilkins, Philadelphia 2000. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35434=[""].join("\n");
var outline_f34_38_35434=null;
var title_f34_38_35435="Drugs that alter phenytoin concentrations";
var content_f34_38_35435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common drugs that alter serum phenytoin concentrations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs that increase the metabolism of phenytoin and decrease total and unbound plasma concentrations include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrofurantoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs that decrease phenytoin metabolism and increase plasma concentrations include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine, ranitidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Omeprazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metronidazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloramphenicol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoxetine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risperidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35435=[""].join("\n");
var outline_f34_38_35435=null;
var title_f34_38_35436="Enzymes gluconeogenesis";
var content_f34_38_35436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and laboratory features of hepatic enzyme deficiencies of gluconeogenesis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Enzyme deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactic acid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uric acid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ketosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum lipids",
"       </td>",
"       <td class=\"subtitle1\">",
"        Response to glucagon",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        G6P",
"       </td>",
"       <td rowspan=\"4\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"4\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"4\">",
"        &plusmn;",
"       </td>",
"       <td rowspan=\"4\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"4\">",
"        &darr;",
"       </td>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe fasting hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some patients have neutropenia, platelet dysfunction, renal disease or hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        F16DP",
"       </td>",
"       <td rowspan=\"6\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"6\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"6\">",
"        +",
"       </td>",
"       <td rowspan=\"6\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"6\">",
"        &uarr;&nbsp;(when fed, not when fasted)",
"       </td>",
"       <td>",
"        Mild/moderate hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscular weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperalaninemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        PEPCK",
"       </td>",
"       <td rowspan=\"5\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"5\">",
"        Normal",
"       </td>",
"       <td rowspan=\"5\">",
"        &plusmn;",
"       </td>",
"       <td rowspan=\"5\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"5\">",
"        &darr;",
"       </td>",
"       <td>",
"        Onset in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated transaminases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulation abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatty liver, fatty kidneys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        PC",
"       </td>",
"       <td rowspan=\"4\">",
"        &uarr;",
"       </td>",
"       <td rowspan=\"4\">",
"        Normal",
"       </td>",
"       <td rowspan=\"4\">",
"        +",
"       </td>",
"       <td rowspan=\"4\">",
"        Normal or &uarr;",
"       </td>",
"       <td rowspan=\"4\">",
"        &darr;",
"       </td>",
"       <td>",
"        Onset in infancy, with early death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe mental retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute necrotizing encephalopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     G6P: glucose 6 phosphatase; F16DP: fructose 1, 6, diphosphatase; PEPCK: phospholenol pyruvate carboxykinase; PC: pyruvate carboxylase; &uarr;: increased; &darr;: decreased; +: present; &plusmn;: may or may not be present.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35436=[""].join("\n");
var outline_f34_38_35436=null;
var title_f34_38_35437="Trabecular BMD hypogonadism";
var content_f34_38_35437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reduced trabecular bone mineral density (BMD) in men with hypogonadism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trabecular bone density (determined by QCT) in 36 men with acquired hypogonadism are shown in the open circles. The solid line refers to the mean values in normal men and the dashed lines are &plusmn;SD. Forty-six percent of hypogonadal men had trabecular BMD values more than 1.0 SD below the mean for normal men. Trabecular BMD correlated negatively with age (r = -0.54; p = 0.003), but the relationship was not significant when corrected for serum testosterone concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.&nbsp;J Clin Endocrinol Metab 1996; 81:4358.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35437=[""].join("\n");
var outline_f34_38_35437=null;
var title_f34_38_35438="Washing catheter chromoendosc";
var content_f34_38_35438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Washing catheter used during chromoendoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 230px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADmAb4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDztaeBV/w5pU2ua5YaZb/6y6lWIHH3QTy34DJ/Cu++LfhfTtMttO1XQbMWtjJJLZyosvmjejHY+7J5dOcdsV9O6sYzUHuzwlTbi5LoebAU8DikUVIorQxACngUAU8CqRIAU4DmnBeKeFpgNC808KaVRUgFAXGBacFp4FOC+1AmR7RilC1Jil280C1IttLt9akxTsUFXIdvtSbanxSFaAINopClT7aQrQBWK0hTirBX0ppWlYCqUqMrVplpjLSHcqFOTTGWrTLUbL6UiioyVEV5FW2SoyvIpNFJ2PFr/wD4/bj/AK6N/OoKsah/x/3P/XVv5mvo74leAfCtv8PtbfRdHtItX07TtPvhJGbhHjWT/Ws7sxjkz2QYI5PPAr5aW7PfWx801Z06zudRvoLOxhknup3EccUYyzMegAqAAkgDk19h/sz/AAl/4R6zj8UeIrcf2tcpm0icc20Z/i9mP6UhnRfCL4YwfDrwg814sc2u3ahrmXH3B2jX2Hc962blfNYyFQAegrsPET4swuep5rh76YgHb0zXm4r4j2cuj7lynfDHGKxpmU8DtV26n2o2SSTWFdTEvXIetGLJ92M46VFNJhcYFR+Z8uMmoJmIBJrWKMpLUjlkwxqqZ+TzzUc8+CTms6Wbng8VZDRrx3QLYJ5qYzhqwoZDvrRVjtzWsDkqJErNnHpULk8/WkJ/MVDJINp+taWMGOkPf1FZ85IqeSQHPNUZWyAD1ppCK8nzMQelRyYQUsjAZFUbu4Cnk1SELM4HA49apG4AfFVZrsliFpsCljuIJ9KGy4xLy3I3Y9DVuJg/I5HSskR79wHUdauQK6KNpxUF8iOU8deH+t/Zpz1lUfzrgj1r3NVEgw4Bzxg15p4z8PHTLlri2Um0kPb+A+lbU6l9GcNejb3kctRS0lbHIe42N3c2NwtxZXE1tcLkLLC5RgCMHBHPIJFSpeXS2LWa3M4s2fzWgEh8svjG4r0zjvVUCpVHavq7I+euKoqQDNIoqRRQQKBT1FCipFFUIFFPApVFOAphcAKeBQBUiigQ0CnAc04CnAUANC04CnhaULQFhmKNtSgUu32oGQ7fagj2qbbxSbaAISOKTbxU23mjaKAINvtTStTlaaV9qAKxWmMtWWWmFaAKrLUbLVplqNlqRoqOtRleRVpk9qiK8igo8M1D/j/uf+urfzNaepeLPEWqacun6nr2rXlgu3bbXF5JJENvTCkkcdqzdR/5CF1/11b+Zr0v4D/C64+IPiES3aOnh+zYNdTdN56iNT6nv6CvlJbs+hjsjtP2ZfhIdbvIvFPiO2/4lUBzZwSD/j4kH8ZH90fqa+vRwMCqtpb2+m2UFpZwpDbQoI4okGFVR0AFWQ3y5qOZFWMTxMQLNjnkCuAvJ8YA6etd14kxJayKDyRxXmt5IwXB7HFcGIV2e7l6tAq3Mh8w4PGO9ZzAsSX69qtSMS3zcelV5W4xXLY9K4xyEGT+FZWoXICnnmp9QuAiHPFc5LM0khOeK1ijORJJMzHrUYGeueKZ6GpEORWiRyzkOBKsT2xVtJ/k5NUJpAit7VTluiCOa0WhjJXNeS5PPb61Ue55IB6H1rJlu3bqf1qA3BDEk1Zm4mw853EZ4qrLcAEHPHU1nS3eAcHPasy4u2IGM1SRNjTur0LnacnNZFzcGVic5quZSxwc5zTgCTQOwi8sK07VlKEMeR0rOZCBkGnxq+3qaTRasaYRcnYeauBSsKnqazbYMB1+arqynKhj07VDLRPknBQEY71LJBFfWbwXCB0cYINVVlO7joO1XLIlmP50RZFSOh5B4q0GXRNQMZBe3fmKTHUen1rDr3vW9Kg1ewktLgfe5QjqreteJ6zplxpN/JaXS4dDwR0YdiK6oSujy61Pld1sevr2qRetRr1qVRX1x8syQVIvamL2qVRTRI9RUiimqKkUVQDlFPA5pFpyigGOUU9RSKKkAoEwUU4CgAU4CgEAFOApQKdigYgFLinAUoHpQA3HtSYqTFGKAI9tJtqXFJt9qAIitNK1ftLGe8Sd4AqxQDMs0mRHH6A46n/ZHNR3Zs54o59Eg1WfTlPlS391GqxPJxgJjpn5uDkjA9a55YmnGoqd9WdCw1RwdS2hRK5pjLVgrimEV0HOVmXAqNl9KsstRsPSkBWK1EVywqyy1Ht+YUho8T0vTV1jxjb6a8hjW7vRAXAztDPjOPxr9EPB/hnTfCHh610fRoRFawDr/E7d2Y9yTX5/eDf+SnaR/wBhSP8A9Giv0cbqa+Uluz6NbIrTjJJ7Cqz3OCFzxUl27ElF6Vj3pIGQelc0nqdlKmpbkWrTqYpADzivNrqUfOvfd3rtryX9wSepFefXhJupMdM8Vy1NT18PFR0BznrVG5kCqe2Ke8j7jv8AwrN1Kb5dprFI7LmRqFwZJGUHIBqmvOfbtT2BZyx6E0KQAc4zWkUZzYj9qiaUJ3NJNJyPSs+5mOePWtkcrJJ7nO7nvVKSXLdajkYknmojknmrSMmyR5AcDrUDyZBA/LNMckDOaReRVIm6GStzVWQ8VbkXiodmSBg80IltEEQ55FTqAWyBUbowzgUxWbOMnNNoE0XzHn0p0GMMpPzVDDIWGDVtEBUuDSHYEBVuasIOScUsSho8kc1KmAhFS0WnYYUyPlqa2lML5PQdaaGyR2FSEKM0tiviNWOVHwwPHrWZ4j0Gy12OEXIKyRnh1HOPSptOJyQfuitLyx1z8vbmri+pz1ILVHPjrUy1CvUVMvWvtD4clTpUq9qiTpUq9qBEoqRajXoKlUVSEPUU8Uxeop4GTTAeBUi01RT1FACgU8CkAp4GaAFApwFIop1AC0oFA6UtABRTgKuaZptzqM3l2sZb1Y/dX6mpckldlKLk7IpKCxAUEknAA711+h+DxLB9q1x5ba3b5Ujj/wBZIfRR6/y71f0vSLfTHXyV+1Xw/jP3Uqxq3iOHTCZ0f7VrLjZuP3YB6KOg+tcVatOfu0up20aMIe9UOR1TTJmuCvisJYabasRaaJav88o7MxBOAe7Nyf0rN1G8e8eMFEht4s+TbRZEcQPXA9fU9TTr66mvrl7i5cvK5yWNViMVWGwkaWstWGJxkqq5Y6IjIphFSkU0jiu04SEio2FTkVGwoEVmHrTCORU7LTNvzD60mB4z4P4+Jek/9hSP/wBGiv0azlQa/OfwWu74oaQMZzqsf/oyv0UY/uRzXyc+rPpoK8SrdSBQ2KwbqQyOQtaV6+FKr36msW7YQxsS2DiuScrnp0IJK5ga1dFYyoPXgD0rnWhZwcnB61evZfNuCQcqKjxmsHqdafKZl1bhYSQCawNYI8tea665XbE4JwMVxuoLmX5hx2pONjanMy5RhR2PeqUr/eNW7snHU5rNlJ5ppFSmV5pDnr+FVXOTxUs33qrykBeDgitUjmkxjt1zUDzYJ5/+vUUspJPNMRC7c1aRg3qBmycBSas2lvJM2QPlzU1nYmRhx3ro7KxEa9BxRclsxxpxyeual+whFAAzXQCFQQMZ9aSWFcccU7kXOTvIwmQRms10CMT610Op227JUVjTREMcjihsuOpCqDP4VNG5jIDUwDHHOakkjLpnuOlI0si9G6qOejUgbGST37VTjkOArHkVOQz8DpSZUVrqSynKjbUqHzBjODUKKRwwzVu2hLc4qSzQtIzGg9+9XFGetRJwQAe1WEAxzxTRlNXOaXtUy9ahSpVNfbHwhMnSpVqFe1TL2oEyZetSL2qJKlWmiSRakFMBp6/SqAkUU8CmLUq9qAHCnAUi04daAFAp4FIKcKAACnAVY0+xuL+cRWsZd+57L9TXa6RoVvpzqXX7Xfdh/Ch/z/kVlUqqHqbU6Up69DE0fw5JcILjUCbe26gHhm/wrqwsFrZcbbKxQdejNVbV9VttNOblhc3n8MK/dT61xep6nc6lN5l0+QPuoPur9BXPyzravRHTzQoqy3NTV/ETyobfTQYLfu38Tf4VzuMnmlorojBQVkcspubuxuOaQin0YFWSRkU1hxUh4NNancViIimEVKRTCKYiBhUePmFWGXmo9vIoA8V8FcfFHSP+won/AKMr9CZ3Jt17V+evgz/kqGk/9hRP/RlfoPIALdK+Snsz6mj8Jm3Ehw3oK4nxBqDNc+WGwPSur1i6SCF+e1eeSv8AaLws3Y8VwVHqe1Qh7tyYJhAfXrSM20ACpcbgCOlQkgsQB09alAyC+nHlHH3jxiuZvoWkbpXR3PljljlqzJ7iMORih6jTsYEtm5BJ7Vm3FptB6811ZkiYgEcZqvcxRygBRginFGcqpxE0GGrJuiQxC12t9Y5+6MZrmbyxYM3HQ1rFGMqlzDCZOTVy2jy6/wCcUrwbN2etS2jKrbmNWZuSNuyiCouOtaydBxiufivo1IG4VrW1wHXjoaTQr3L6/epWjZ1OOlPiXIH58UTMFwADUjsZN1FgsDWFfR7TkV0F02/ce/esa+B5qlsOLsZiqCfcVYVN0eO9RL/rOPzqwDjaSeKRrcz5Bsm4qeCVgenJqK4I8529aSFiSvBqWbR1Ny3iU4J+tXFXaxwODVW2I2gjPIq0uR1/CmiSxGMkdQatBeOahjQjgjNWFTaeuM0WJlscotSr1qFTUi9a+1PhGWENSqagQ1KpoJLC9alWoFNSqaBEy1KtQrUiGqQiZakXtUKmpVNMCVetPWolNXdOsrjUJxFaRM7nr6L7k9qTaWrGk27IhFdJovhqa6UXF+Tb2vXnhm+npW3o+g22mujSAXd/1A/hQ/5/yKsavq1rpnN04ubwD5YEPyp9a5Z13J8tM64UFH3qhbgjhs7MiEJZWSDJkbhmrnNX8TZRrfSQYYjwZj99vp6Vh6rq11qc2+5k+UfdjX7q/hVLNOFBLWW4p129IjmJZiWJJPJJ70Y9KSl7Vuc4oFGKAfWjNABikpTTaAEPSmnpTycU2gBlNPWnnrTD1pisRt0pmORT2FNP3h9aaYmeIeDTj4n6Sf8AqKJ/6Mr9ALiUJaKxNfn74R/5KZpf/YUT/wBGV9/6lZyy2aLF1r5CvK0WfWYblsuY4bxBdtLIwVuPSuetx+89M11Gp6PIisSCWrAltZITyCTXl6t3Z7yq0+WyY9mCR4FUbiXyweetSksBluD6Vi6rc7Q2T0rS5mo3Ib6+xkZ5rCnvcvkNj1qtf3ZJODWZJMeMU4q45WSNc3xAHzfjT01L5fv/AJ1zklzjOTVX7XukC7ua3UTkmdzBexTEhyD6VBe2ysrFOlc/Z3OHAHbqa6GznWWLHcdataHFJnL39vtZjzmseZWDEgV2+o2qsSR161h3Fsu/A596u6Ers5oQyll2k5zXU6TuSAbj84qGC0UMCfyrTtbfLHFTJ3Lj5mrauSAfakn6+1OhQoDmiYEj5eazNkzHupBHuIPesC7vw0hUc4q1rd2RIyJ1z1rAkba+Tzmnc3hBPVmjEQ5BBwauYATPaswHMStgitFcPBjpj1pJjlGz0M+cZlJNTW+d4yKaVy4wOlXbaHjd1oZUWaVlF8uT0q7syTilsYgkHI59Kn2AHNIlskjjJXP5VOqjA7GnQjCYpduelMiT0OHQ1MpqspqZGzX2aPiGiwpqVTzVdalU1RBYU1MpqshqZDzQIsKalU1XQ1KpxTJJ1NSKafptlcahcCGziaWQ9h0HuT2FegaH4bttMdHuALy/PIQfdQ/57n9KidVQ33NadKU/QwtC8MTXiC4vmNradfm4Zh7DtXa28UNlZf6OFsrFfvStwzf59aqa1rFnpXN4/wBpvMfJboeF+tcLrGs3erTbrqT5B92NeFWudKdbV7HTzQoaLc6DWPFOFa20YGOI8NOfvN9PSuWLFmJYkknJJOSahBp4Oa6YQUFZHLOo5vUkBpwqMGng1Qh4NLTAcmlpAOpaaDS96ACignFJmgAJppNLTTQAhpp60pppNADSc0zuKcaZ/EPrTE0eJeCwD8UtHB6HVY//AEaK/RgrjjHTivzf8NS+R8RNOl/uamjf+RK+95/F9vHGpIyx618nPS9z6NXUbnQ3FrHOCHUc+1Y+oaDCykqMfhWVP43gUHGAaz7jxujjAIArnlCL2EqjWxieJLL7Lkg4xXm+rXJZn5I5rsPFGvi5UkGvNtQujJK2DwTWTpnpYau2rMq3R3yHH51RuHIXdmrEmeTn61nXbEpnPFUkdTmUbm4zkd81XjlIcnOTRKuc4zUljCsk4Mh+UfrWqVjmqSLtrcHcASa6XSZNgGSfmNYBtC1wFjHOa27S3eCXy5DyDxQzB6nRzxiSHPfFc9dIEl44xXQKTsGTwaxNSTMzbOnvU3KjFlKKQbsZz71fgmAbjFZLAqeeuakjchT70GnIb323aPeq89+TGcEA47Cs5pDjaTVV5GwRmkUomVcSbriUuSeT1qhgeeCwJWtC4iBlPXHeoigLBVFS2dkfhHO/yAD8qkhMhXHY9qtw6eSgYDk1qWGmHIdgSO1CJk0Q2OlsRuf7x5xWoLMJjAGetX44CgwAelIynOO9XYx5ivHxwetSoRu56U9Ie5qRY+opXAQghfk5pQSO9SxLg4JqKQENx0pIb2OEQ1MpqspqVTX2SZ8ZJFlTUqmqyGplPFVcyaJ1NTKarqavaZZXOo3S29lC0srdh0A9Sewp3FZsFPFdV4d8J3OoItzek2tl13Nwzj2H9a6Dw/4TtdKaOS+AvdR6rEoyiH/Pc1q67rVno6htRkFxd4zHaRnhfr/n86551m3aB0QoJe9MtWVtbafYkWapZWSDLzvwW98n+dctrXi9UR7XQ1MaHhrlh8zfSua1zxBe61Nuun2xA/JCnCr/AI1mq1OFHrMmpX6QLJkZ3LuxZickk5JpwNQKaeDXQjmLANOWoQaeppgiYGlqMGnA8UMZIDSg1HmlBqRktFRg0oNAElFMzQTQApNIaTNNJoACeKaT60E0wmgAJpoPIpCaaG+YUxM8H0k7fG9sfS+B/wDH6+iNX1wpGAG5z1r5wtn8vxUj/wB27z/4/Xp2qX7uSAxPOc18nU1uj6WnrGx0k+vuf4qg/wCEgbpmuSDO+Dk4qVYmbtWKNVTN281oyocHn61mxXRcnjvVdbctjiraQCNc4wBSZrTVmWGl3piqdzGdgUUoYhz83ApGcnGeRQkbSY2GyXyCXIBqNIlQ5AzzxVld0g46dqVIWLDjiq0Mty1aMVVpOrHge1adkGdlZ8k5qlbxDePpW9p0WMAAYqLlKBbYkIMisi8ZS7ZOD61qahL5SZPAx09K5u6lY/MTxnilc1hAhn4YZzRE2Qc+tVZZ8gEmn28owR70XLaNNIgQc4570w2y96YsuOh5qzGryKCooEipLbx4PHOagt7DfPkDArUW2eQ9CRWtp9hgZZRnsKLBz2K9jY4Kllx7VrwWoVeBkZq1HbBVzVuOMIOlFiXK5UaABcmqjwjceM1rON2fXFV2i+bpQNFDygAOM0eX1HargiOeaY8fPqKhmiK7JgjFRmMZ55q0VKZJGeKaoBGeaLgzy1T71Mpqsp4qVWr7JM+OaLKmpVYUulWF3ql2ltYQPPM3ZR0HqT2H1r1Tw14Ks9IaOXUgt/qXVYFGUjP07/U/lRKookqm5HNeF/B13qyrdXhNnp/XzH4Zx/sj+p/WvStOtLTS7ArYIllZIMyXMnDN75PWqfiHXrHREDapIJ7vGY7KI9Pr/if1rzDxD4m1DXps3Umy3U5SCPhF/wAT71jaVX0NLxo+p12v+N0iV7Xw8CoPD3bj5m/3f8TXEPM8sjPK7O7HLMxySfc1TVqkVs10QgorQ5pzcnqWg1SK2cVVVqlVqszLKtTw1Vw1PDflQIshqcGquG4p4NVcRYVuKcGqANTg3HWmMnDUoNQq1ODVLC5MDS5qHdS7qQybNJmo91G6gY8tSFuKZmkZqAFJppNNJppPNAhSaaDhh9aaWpu7kUxXPAXO3xA59Lk/+hV6Gf3g69686n/5Dkh/6eD/AOhV6JC42ivk6m7PpqRZtY8kH9K0BGFXI+pzVKGUA5PpTp7xAuA3FY2OqLLKkbxjrRc3AVMCsR9QwSFPJNRNOzEl80NGkI3NQSjJPAzSxvkAGskTkEYq1FNk8k560WLcWbURJCqBwK0LeMMvGMVl2suVBzWzasCwPFSwjEt2cAaReK1oYfK5z0NQ2O0YY9KkurpFQqpqLjsZesyE7hkn2rnZZTnBBJrau38wkZqtbW4mfBGaLmqjbUwWBYgdee9XLWEnOBn6V1tnpEMirlBWjFo8ceSAMe1NIHOxysGnyttIXr61u2ViwRVYVvW9mucYHA6Veis8AYFOxi5mTbWI/u45rQW2CDOOKvxxBR75pzrlSM09iL3KioNuMCom4yPerIXB9qhkT5yRUtmijcYg60qplsdBT0jxycVOIyfp60rlWKcseF6VX2ksT2FaLJkVE0WFLelQUmkUWiDHnNROApAFXNpOenNVXHzU1oVuePK2Bmu38I+Br3WFW7vybHTevmOPncf7IP8AM/hmut8K+BLDRWjl1JV1HVeCsIGY4z9O/wBT+VbXifxJp3h9N2rSi5vsZjsYT93/AHvQe5/WvrHUeyPlHFMv6VZWWkaayackdjYIMy3UpwW98nr9a4rxJ8QY4kks/DK4B4e9kHzN/ug/zNcV4m8Wal4inzeS7LdT+7to+EX/ABPuaxVbjrVRp9ZESk1oi688k0rSSu0kjnLMxySfUmnK1VUapVat0c7RZVqlQ1VVqkDelUZtFpWqQNVVWqQNTJsWQ1SK1VQ1Sq1AFkP+dPDVWDc9aeGpisWA1ODVAGpwagRYDcc0oaoA3FKGpAWN1KGqANS7qAuThqC1Qg0Z96Bpku6kLVHu96QmgGPZqYW9aYWppNAIeWpm75hTWamhuRTGeDXZxq85/wCm7f8AoVdvDPiIHIrhr3/kK3H/AF2b/wBCrqYWaRAMjH8q+Tnuz6Sl5Fye8bkKRiq6ySzYwTVmKz3H5quRRLGPlA96xckd0KTZSjtxGoLHk1HLNtJ9AeKsXD44A4rKuX6+tC1NmuVFpLhcnkdatRScjnr1rBQktjtVuOVhtHam1oSpXOmtbjAGa2LW9VWG484rjY5zwKtJcsDkdelZu5tFHbJqvG0HimNePKQBkg965i2keRxg49a6CyibaoANSWopF6KBpGGTk1v6Zp20dOTVfSLQuoY9a6W1h2YpIUmV4ITBIBWjHyPWpniV1HGKXy8KcVaZi9SKNcPkZrQjxtBqvEBggjmrMYwNp7UrkOI1ufzpjg88VYVACfeneVuQkUmw5SiQT2zTmi+T3qdo9rdaa7/LgYqbmkVcrqMkLVhAMdhUaj5sjj1p7vtyeOlK6ZTiV0/1nPSnXAG0qvenouMMec01xuJJoB6FRo9oxjjFUpRhsVpzEAYrOuRhx9KLDTuYXiv4lJEklj4UUop4kvpB87/7oPT6n8u9eZSTSTStLM7SSOdzO5yWPqTXLDxLEP8Al3f/AL6FOHieIf8ALs//AH0K+mjiKS6nzTpS7HUq1SK1cqPFMQ/5dpP++hSjxXEP+XWT/voVosXS/mIdGXY65WPrUqtXHjxbCP8Al1k/77FOHjCH/n0k/wC+x/hVLF0f5jN4efY7JWqRWNcYPGUPezk/77H+FOHjWH/nzl/77H+FP65R/mIeGqdjtVepFauIHjeAf8uUv/fY/wAKcPHMA/5cpf8Avsf4U/rlH+Yh4Wp2O5Vqer1wo8dwf8+Uv/fwf4U4ePIB/wAuMv8A38H+FNY2j/MT9Vq9juw2KeHrgx4+tx/y4y/9/B/hSjx/AD/x4y/9/B/hT+u0P5vzF9Vq/wAp3wenBq4AfEG3/wCfCX/v4P8ACnD4h24/5cJf+/g/wo+u0P5vzD6rV/lPQA1KGrz8fES3/wCgfL/38H+FL/wsW3/6B83/AH8H+FH12h/N+YfVav8AKeghhS7jXnw+Itv/ANA+b/v4P8KX/hY1v/0D5v8Av4P8KPrtD+b8w+q1f5T0ENil3157/wALGt/+gfN/39H+FH/Cxrf/AKB03/f0f4UfXaH835h9Uq/ynoJekL15+fiNb/8AQOl/7+j/AAo/4WNb/wDQPm/7+D/Cj67Q/m/MPqtX+U74tTS1cEfiLb/9A+b/AL+D/CkPxEtz/wAw+X/v4P8ACj67Q/m/MPqtX+U7stTd3IrhT8Q7f/oHy/8Afwf4Un/CwrfI/wBAl/7+D/Cj67Q/m/MPqtX+U4W+/wCQncf9dm/9CNdNp7jaPeuVnlE13JKAQHcsB6ZNdDpjHHXpXzs9bnvUnY6S3JK80+Z8LgVXt3+XGfxNOuHwBWDR6UJaFG5fOee/SsydhuPpmrc7cHHI9aokFmxiqiKRIif/AK6sKp2g4ohTHXtUuOB79qGyoRETtVmJSxI9ajVeBg960bGHcefwrJs6IxNPR7bDAHmu60qzRoVG0ZrmNMiJdeK7fSkwq+lSgmy1bQmBypFbFugbBGDVdU3jG3kd6v2iEMB1FMxvcnSPCimmLDcdM1ajjyuTUxhDdKRJVjgw3I4qYW+4AgVYWPj6VIowKVwuU2jKsalUAL6HvUuMk8UxgRlfWi4itOoHNVvLEje9WymWw1KsRA4FIpaFQx4GPSoym/rV2QfKcdKqAMSe1LYpNsa2MqtOcYz0zULsQSeMjpUisW69cdKYmmV7hcLmqMikt6j1rRuDnj/9VUGOMjoKFqPZHx/RRRXceMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADk+8PrXV6LCJULMflz0rlE++PrXU6XciKDaTjnPNJjjub6wKF+Xr61FdRlVznIFRxX6bfXPpUc90Zl2DgCoZ2UmUXO5x60iL83GKk2c5xTkAwOOazudUVccF6dKXaSeO1A5IFTwplge1Js2ih8KcitnS4t0gwPrVW3VenGSeK2tPAiYY4FZtm6Ssb+lW2JFNddpsHyiud0gFyDjmuu05ThfTvTic9UuwL5ZyRkHirUce1sjoakSIMnPTNWYUDR4I5HFU0c/MTWyhkAp5ix0qBcwMD1Bq4jB1zmpsF2RBe9JtI9zVgJSMuMGkx6ERBxnFN2AkknrVvGU6c1FKhxwOamzC5EIwQRmk8sAYqwiHAyOaZJkA8d6YX1KN0NoOB2qoQcD3FaEo3Z9cVWl5OD+FS1cd7FCVMjGKaqlB8xqy6gbeenWq0rgMcninYfMRzNyfQ1nTnD/WpLibqC3FUzKGbmmh20uz5LoooruPHCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBV4IPpWxayB0DL0/lWNVmzn8mUZ+4etA0bsbHj0q1H1B9apAgYIOVbkEVagfjnr0qGdNKRZxxxRjAHrQGGPYU0tlvrWJ3wHA/N71biOB7VTHWrMOSRjr0qWbxNCBuQQK39PTcRuHXpWFbR5xXQ6cPmGDyDipZpc63SExtPpXY6ag2AHpXLaSBtQHrXU2MgQjuKqJx1WbMcfAx+NO+44YdaZE42HHen+ZzVs5k3cmYBkBPenRphevemRNgZFSM3BrNmiZJ5hAxTWbjmodw/Gjdkc1LL0JhJgUvmbuDxUBOaaz7fwoFYtmUEjimOQfWqTTbgB+FKk5HDdqBbD34OOtQzAAj0prSZY88VWluAMigWo2cjdnpWZcyE7yOvepLi4wcVm3VwSxHamXFEM75O3HvXM+K/Fll4bWEXPzzS9Il6hfU1d8U69a6Fpst5cnOOI07yN2Ar521zVbnWdRlvbx90sh6dlHYD2rSnC+pnXrcistzPooorpPNCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApRSUUAXrK7KDynPynofSti2OR1zXM1o6ddbWCN+BpNGlOVmdDGPl980vrjmq8Uuceh96nBDYxxWElY9KnK6JEUbvr0rQt4898VSUYNW4ScZqDpRpQgA4rb04gN1rn4nyR/OtbT5Pm57VLLO702T5ExXRWUgK4zzXG6bcjC1v2twQRg1cTlqI6mCXnBqyG4HrWPbT/Ke4q5HMMAHvTMLamgkowMn8Ke0oweeazRJzTTMSSCaktI0BL8oprS4GRzVFpcNx0pWlAAyallWLyzcHGM0SMMZ3Cs8T4Joa4BzSCxOzYwQageVux+tQtJ7/AI1C8wzg0xFkz9fmwarzPuz7VA8o3e1QzTDgk80hBK3NUr/UbDTtNvLnU/ljRMq4PQ/1pJ7lUQtIwVAMkk9K8I+JPi5tcvmtLJ2GnwnHp5jev09KuEeZiqVFCJj+MvEdx4i1Rp5CVt0+WKPPCj1+prAopK6kraHmyk5O7CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaKKANWwnZlwc5HFasRPBoorOR3UG7FtGwParMbEEUUVkz0IlmNsBfer9pIVbHNFFQy0b9hcMNvWulsbg4FFFNGU9jatpyRxkZrQhm5HBoooZzsmWTnFJ5nU96KKkaGmUk4qPzieDRRQzRDHmIBIzUfnHBNFFBLDzzgdajMu496KKZDIpZcFwc1Wlnyp4oopAzyz4reJ54saTagxhxulf+8PQV5Q3WiiuuCtE4Ksm5aiUUUVRkf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Washing catheter for chromoendoscopy (A) creates a fine mist spray (B) necessary for optimal application of reagents to the gastrointestinal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcia I Canto, MD, MHS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35438=[""].join("\n");
var outline_f34_38_35438=null;
var title_f34_38_35439="Struvite crystals";
var content_f34_38_35439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing struvite (magnesium ammonium phosphate) crystals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing multiple \"coffin lid\" magnesium ammonium phosphate crystals that form only in an alkaline urine (pH usually above 7.0) caused by an upper urinary tract infection with a urease producing bacteria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_38_35439=[""].join("\n");
var outline_f34_38_35439=null;
